Pituitary: An interesting "pineal incidentaloma" in a case of nephrogenic diabetes insipidus
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**Introduction:** Pineal masses are not uncommon in the pediatric age group. They may be associated with central diabetes insipidus (DI) due to concomitant involvement of the pituitary stalk especially seen in germ cell type. However, pineal incidentalomas are also common and found in 5-10% of autopsy series.

**Case Report:** A 6-year-old female child was referred in view of polyuria and polydipsia since 6 m of age. In view of difficulty in performing biochemical evaluation, outside she had undergone magnetic resonance imaging (MRI) brain and a pineal mass was detected with no evidence of posterior pituitary bright spot. Patient had no response to inhaled desmopressin. With this history, she was referred here. There was no H/S/O hypothyroidism, hypocortisolism, raised ICT, polyphagia, behavioral or sleep disturbances, recurrent urinary tract infections, hemoglobinopathies or any drug intake. O/E -- weight and height were appropriate for age with normal general and systemic examination. On evaluation, urine output was around 7000 ml, euthyroid, normal glucose levels, calcium and potassium. Water deprivation test was suggestive of complete nephrogenic DI. Renal evaluation failed to reveal an acquired cause of nephrogenic DI. Contrast enhanced MRI did not show any increase in the size of the pineal mass. Patient responded to thiazides with a decrease in urine output to 2500 ml and is under follow-up.

**Discussion:** Despite the presence of an obvious radiological lesion (pinealoma) biochemical evaluation for polyuria and polydipsia should be performed. In this case, biochemical evaluation was suggestive of nephrogenic DI. Most of the cases of nephrogenic DI are acquired. However, presence of symptoms as early as 6 m of age suggests the possibility of hereditary cause. Among the hereditary causes 90% are due to arginine vasopressin receptor defects.

**Conclusion:** This case reiterates the concept that initial biochemical evaluation should be performed prior to radiological investigations.
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The clinical, biochemical, and radiological features of nonfunctioning pituitary adenoma at presentation
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**Introduction:** Nonfunctioning pituitary adenomas (nfpas) are the most frequent type of pituitary tumors. because of hormonal inactivity, patients bearing this tumor type often present late with macroadenomas. they commonly present with headaches, visual field defects, and symptoms of hypopituitarism in 5th and 6th decade of life.

**Objective:** The aim of this study was to evaluate clinical data at presentation.

**Materials and Methods:** we analyzed the data of 84 patients of nonfunctioning pituitary adenoma retrospectively.

**Results:** Total 84 patients data was evaluated, of which 44 were male and 40 female with mean age of 44.05 ± 12.75 years. thirteen patients were below 30 years of age. common symptoms were visual disturbance in 74.99% and headache in 70.23%. hypogonadal symptoms (i.e., loss of libido, impotence, oligo amenorrhea) were observed in 42.5% of female and in 37.9% of male patients. hormonal axes involved are growth hormone 32.35%, gonadal 32.14%, cortisol 32.14%, thyroid 10.71%, and diabetes insipidus 2% patients. maximum tumor diameter was from 0.3 to 6.9 (3.32 ± 1.05) cm. 66.66% showed suprasellar, 29.76% parasellar, 9.5% infrasellar, 1.1% anterior, and 1.1% posterior extension.

**Conclusions:** This analysis gives a complete overview of patients with nonfunctioning pituitary adenoma.
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Bone and parathyroid: Molecular characteristics of large parathyroid adenomas
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**Introduction:** While the risk groups of familial and malignant Primary hyperparathyroidism (PHPT) have been partly elucidated, less is known about sporadic parathyroid adenomas with severe clinical and pathological features. It has been speculated that large parathyroid adenomas could also be associated with a malignant potential.

**Materials and Methods:** We report results from APC and parafibromin expression analyses by immunohistochemistry in 10 cases of atypical adenoma, five cases of carcinoma, and 30 adenomas without atypical features.

**Results:** Complete loss of parafibromin expression \[[Figure 1](#F1){ref-type="fig"}\] was seen in five out of five (100%) carcinomas, and 20 parathyroid benign tumors (mean weight ± SD of these 20 adenomas was 5,215.78 mg ± 5,805 mg, range being 200-21,600 mg) stained positive for parafibromin \[[Figure 2](#F2){ref-type="fig"}\] out of 30 (66%) whereas five of 10 atypical adenomas showed complete loss of parafibromin expression. The sensitivity of parafibromin as a marker was 66% with specificity being 50%. APC was 82% sensitive and 14% specific. On combining both parafibromin and APC, the sensitivity was 80% and specificity 50%.

![Parafibromin negative](IJEM-17-373-g001){#F1}

![Diffuse parafibromin positive](IJEM-17-373-g002){#F2}

**Conclusion:** A subset of large parathyroid adenomas share molecular characteristics with parathyroid carcinoma and typical adenomas. Thus, APC and parafibromin together could become a valuable tool when assessing parathyroid tumors in the clinical setting.
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Effect of lactation on bone health and body composition of urban Indian mothers up to 1 year postpartum
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**Objective:** Lactation is highly active phase for bone turnover. Objective was to study change in bone parameters and body composition in higher socio-economic status urban Indian women up to 1 year postpartum (PP).

**Materials and Methods:** A longitudinal study on randomly selected 50 primiparous (27.8 ± 3.5 yr) PP women (within 7 days) was performed and 22 women were followed up at 6 months, out of which 10 were followed till 1 yr PP (data addition is ongoing). Data on anthropometry, body composition, bone mineral density (BMD) at total body (TB), AP spine (APS) and dual femur (DF) neck region by dual energy X-ray absorptiometry (DEXA) was collected at baseline, 6 months and 1yr PP. Statistical analysis was performed using SPSS software (version 16), using paired '*t*' test to compare means at baseline with 6 month and baseline with 1 yr PP.

**Results:** Preliminary data-analysis suggest that there was decrease in weight (8% and 11%), waist (8% and 7%) and body mass index (BMI) (8 and 11 %) was seen both at 6 month and 1 yr PP respectively with respect to baseline. Lean body mass (LBM) decreased significantly at 6 month (8%) with further reduction (11%) at 1 yr (*P* \< 0.05). Bone mineral content (BMC) and BMD at all sites decreased initially at 6 months, however, at 1 yr significant increase in BMC and BMD was observed (*P* \< 0.05). When BMC was adjusted for LBM (univariate analysis) at 1 yr, there was further decrease in BMC as compared to 6 months, indicating effect of decreased LBM on BMC. Significant increase in android fat was seen at 6 month and it remained elevated at 1 yr (*P* \<0.05).

**Conclusion:** Along with reduction in weight, waist, and BMI, LBM and BMC also decreased at 1 yr PP in conjunction with increase in android fat percent indicating risk for low bone health after weaning.
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Effects of denosumab in postmenopausal women with osteoporosis from India
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**Purpose:** To determine effects of denosumab (DMAb) in postmenopausal osteoporotic women from India.

**Materials and Methods:** Double-blind, multicenter study. Two hundred and fifty Indian postmenopausal women from 55 to 75 years of age, with osteoporosis (dual-energy X-ray absorptiometry bone mineral density (DXA BMD)) equivalent to a T score of \<−0.5 and \>−4.0 at either lumbar spine (LS) or total hip (TH) and serum levels of 25-(OH) vitamin D ³20 ng/mL were randomized to DMAb 60 mg subcutaneous (SC) injection or placebo. BMD, serum bone turnover markers (serum C-terminal telopeptide of type I collagen (s-CTx) and serum procollagen type I N propeptide (s-PINP)), and safety were evaluated. All subjects received daily calcium (≥1,000 mg) and vitamin D (³400 IU). All sites obtained Ethics Committee approval and all subjects signed informed consent.

**Results:** Baseline age and years since menopause were similar with mean 62.6 years (standard deviation (SD) 4.96) and median 15 years since menopause. At month 6, compared with placebo, the DMAb group showed a statistically significant increase in percentage change in BMD from baseline at the LS (primary endpoint) (3.1%; 95% CI: 1.9%, 4.2%; *P* \< 0.0001), TH (1.7%; 95% confidence interval (CI): 0.9%, 2.5%; *P* \< 0.0001), femoral neck (FN) (2.3%; 95% CI: 1.1%, 3.4%; *P* = 0.0001), and trochanter (1.8%; 95% CI: 0.8%, 2.8%; *P* = 0.0006\]. A decrease in percentage change from baseline was observed for s-CTx (median: −33.4%; 95% CI: -40.8%; −26.0%; *P* \< 0.0001\] and s-PINP (median: −37.6%; 95% CI: -44.2%, −31.2%; *P* \< 0.0001). 31% DMAb and 37% placebo subjects experienced adverse events (AEs). The most common DMAb AE was upper respiratory infection (6%) vs 2% in the placebo group. One subject (DMAb) and three (placebo) experienced serious AEs (SAEs), none attributed to study drug.

**Conclusions:** After 6 months, DMAb statistically significantly increased percentage change from baseline in BMD at the LS, TH, FN, and trochanter; and significantly decreased percentage change from baseline s-CTx and s-PINP compared to placebo. No new or unexpected safety signals were detected. This study was sponsored by GlaxoSmithKline Pharmaceuticals.
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Bone health was studied in 26 patients (20 allogenic, six autologous) who had undergone hematopoietic stem cell transplant (HSCT) over a follow-up period of 1 year. The mean age and body mass index (BMI) of the cohort was 24.4 ± 16.4 years and 19.4 ± 4.5 kg/m^2^, respectively. There were 17 males (65%) and nine females (35%), of which 15 were adults (58%), six prepubertal children (23%) and 11 adolescents (42%). The bone mineral density (BMD) declined nonsignificantly from the baseline at the whole body (TBMD) (% change: −2.8 ± 5.5, *P* = 0.748) and the lumbar spine (% change: −4.6 ± 8.7, *P* = 0.130) at 6 months posttransplant. There was a significant decline in BMD from the baseline at total hip (hipBMD) (% change: −9.1 ± 9.7; *P* \< 0.0001), femoral neck (FNBMD) (% change: -4.0 ± 9.6; *P* = 0.003), femoral trochanter (FTBMD) (% change: -4.7 ± 10.4; *P* = 0.001), and Ward\'s triangle (WBMD) (% change: −11.4 ± 10.7; *P* \< 0.0001) at 6 months posttransplantation. From the 6 month posttransplantation to 12 months posttransplantation, there was significant improvement in TBMD (% change: 3.9 ± 5.1, *P* = 0.014), hipBMD (% change: 9.7 ± 11.2, *P* = 0.014), FNBMD (% change: 5.1 ± 5.1; *P* = 0.002), and WBMD (% change: 3.8 ± 5.7; *P* = 0.036). There was a trend towards recovery at lumbar spine and FTBMD. Comparing the BMD from baseline to 12 months posttransplant, only the decline at Ward\'s triangle (% change: -8.4 ± 9.5; *P* = 0.005) was statistically significant indicating persisting bone loss at Ward\'s triangle at 12 months posttransplant. Decrease in BMD had significant negative correlation with age, BMI, and hypoadrenalism; but showed no correlation with fat mass, lean mass, serum 25-hydroxyvitamin D (25(OH)D), serum parathyroid hormone (PTH), and other endocrine deficiencies like hypogonadism, hypothyroidism, growth hormone deficiency, and new-onset diabetes after transplantation (NODAT). Allogenic BMD had more effect on hipBMD, FNBMD, FTBMD, and WBMD than autologous BMD at 6 months post HSCT. Graft-versus-host disease (GVHD) had no effect on bone loss at any site. The intake of immunosuppressive therapy had a statistically significant effect on the change in FNBMD (*P* = 0.010), hipTBMD (*P* = 0.047), FTBMD (*P* = 0.021), and WBMD (*P* = 0.039) at 6 months post HSCT. Steroid use had a significant effect on the WBMD (−15.9 ± 9.7%; *P* = 0.006) and hipBMD (−12.5 ± 7.9%; *P* = 0.038) at 6 months post HSCT with no significant effect on other sites. Patients with leukemia had more significant change in FNBMD (-8.8 ± 4.4%; *P* = 0.002), WBMD (−13.0 ± 7.0%; *P* = 0.035) and FTBMD (-7.9 ± 3.6%; *P* = 0.040) when compared to patients with multiple myeloma (MM) at 6 months post HSCT.

**Conclusions:** Maximum bone loss is observed at 6 months in patients with post HSCT, which showed recovery at 12 months post HSCT. Bone loss was highest at Ward\'s triangle followed by femoral trochanter, femoral neck, total hip, lumbar spine, and whole body. The bone loss is predominantly at cortical bone. Younger age, low BMI, hypoadrenalism, allogenic transplant, immunosuppressive therapy, and steroid use are all related to bone loss in patients undergoing HSCT. BMD should be performed in all patients undergoing HSCT at 1 year posttransplantation to assess the bone health. Most patients who recover from bone loss may not require any therapy. Those patients with persistent low BMD may require long-term follow-up and antiresorptive therapy.
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**Introduction:** Parathyroidectomy is the standard treatment for primary hyperparathyroidism (PHPT), however, though the onset of biochemical response is variable and is different from one patient to the other.

**Description of the Case:** We are reporting a case of a 37-year-old man admitted with complaints of anorexia and recurrent vomiting. He was found to have acute renal failure (serum creatinine: 3.5 mg%) and bilateral nephrocalcinosis along with PTH dependent hypercalcemic crisis (serum calcium: 15.5 mg% and serum intact PTH (iPTH): 1,500 pg/ml). A palpable firm nodular mass in left paratracheal region was detected. He was optimized with saline diuresis and calcitonin. Both ultrasonography (USG) neck and technetium (Tc) 99 m Sestamibi scan showed a concordant imaging with a large solid cystic mass at left side of lower neck. Parathyroidectomy with bilateral neck exploration was done keeping in possibility of the parathyroid carcinoma. Peroperatively, we found a large gray-white globular solid cystic mass adhered with left thyroid lobe. En bloc excision of tumor with hemithyroidectomy and central compartment lymph node dissection was done. Other parathyroids were normal in size, shape, and location. Next day morning serum calcium and iPTH was 14.2 mg% and 2.5 pg/ml, respectively. Serum calcium decreased gradually with a nadir of 7.4 mg% on 4^th^postop day. Histology showed a parathyroid adenoma.

**Discussion:** The majority of PHPT patients become eucalcemic quickly, however about 14% had a delayed normalization of serum calcium for more than 3 days.

**Conclusion:** Successful parathyroidectomy quickly leads to serum calcium normalization with a subset of PHPT patients will need more than 3 days.

**Key words:** Parathyroid carcinoma, parathyroidectomy, PTH dependent hypercalcemic crisis

Prevalence of male osteoporosis and the influence of lifestyle factors, calcium intake, and vitamin D status on bone mineral density
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**Introduction:** Osteoporosis in men is underdiagnosed and undertreated. There are no major studies regarding the prevalence of male osteoporosis in India. The current study looks at the prevalence of osteoporosis in healthy men above the age of 40 years.

**Aims and objectives:** (1) To study the prevalence of osteoporosis and fracture in male subjects. (2) To study the influence of body mass index (BMI), nutritional calcium intake, vitamin D status, and lifestyle factors on bone mineral density (BMD). Subjects and Methods: We surveyed the number of male subjects above the age of 40 years in Velapadi segment of Vellore. The sample size was calculated using proportion tests based on absolute precision of 80% and confidence interval 95%. Total 113 subjects were included in the study who met the inclusion criteria.

**Results:** Out of 1,241 males; 97 subjects have sustained single or multiple fractures. The mean age of the study subjects was 56 years. Mean corrected calcium, Vitamin D, and parathyroid hormone (PTH) level in the study subjects was 8.8 mg, 20.4 ng/ml, and 44.2 pg/ml. In spine about 15% of subjects have osteoporosis and 47% have osteopenia. Femoral neck osteoporosis was seen in 10% of subjects and another 52% have osteopenia. Forearm osteoporosis was seen in about 30% of subjects and only about 31% have normal BMD. There is a statistically significant correlation between BMD and BMI in all three sites. The study shows statistically significant positive correlation between nutritional calcium intake and BMD. Increased physical activity positively correlates with BMD at femoral neck and forearm. There is no correlation between alcohol intake and low BMD. The mean BMD in all four sites was lower in subjects who smoke, but not statistically significant. In logistic multiple regression analysis, femoral neck BMD was associated with BMI, physical activity, and calcium phytate ratio. At lumbar spine it was associated with BMI, calcium phytate ratio, and intact PTH (iPTH). At forearm BMD was associated with BMI and age.

**Conclusion:** (1) This cross-sectional prevalence study shows that osteoporosis of lumbar spine, femoral neck, and forearm was seen in range of 15, 10, and 30%, respectively. (2) BMI, physical activity, and nutritional calcium intake is positively associated with BMD.

Oncogenic osteomalacia-10 years' experience in a tertiary care center
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**Introduction:** Oncogenic osteomalacia (OO) is a paraneoplastic syndrome seen in tumors of mesenchymal origin. They secrete 'phosphatonins', like fibroblast growth factor-23 (FGF-23) that inhibit the renal tubular reabsorption of phosphates. They are characterized by hypophosphatemia and osteomalacia. The patients make remarkable recovery once tumors are localized and excised.

**Objective:** To study retrospectively the clinical, biochemical profile, and follow-up of the subjects who presented with the features of OO to our department.

**Materials and Methods:** Clinical, biochemical, and radiological data of all the patients diagnosed to have hypophosphatemic osteomalacia (HO) from 2004 to 2013 were collected using the computerized database. The patients with proven OO were analyzed.

**Results:** Among the 43 patients who presented with features of HO, nine were diagnosed to have OO. The most common presenting symptoms were bone pains and proximal muscle weakness. The average duration of symptoms before initial presentation was 5 (± 2.12) years. The most common site of tumor was nasal cavity. The mean age of presentation was 41 (± 11.4) years. The average serum corrected calcium, phosphorus, tubular maximum phosphate reabsorption per glomerular filtration rate (TmP/GFR), alkaline phosphatase, 25-hydroxyvitamin D were 9.05 mg%, 1.7 mg%, 1.1, 327 U/L, and 36.5 ng/ml, respectively. FGF-23 was available for only three patients with a mean of 209.3 (± 69.47) RU/ml (reference interval 21.6-91.0 RU/ml). The tumor was localized in five patients at initial presentation and the rest on follow-up. All patients underwent surgical excision, of which two are in partial and six are in complete remission.

**Conclusion:** Screening for OO should be done in patients with HO. The head and neck region is the most common area of tumor occurrence. A high index of clinical suspicion, selective imaging, and follow up is needed to recognize this condition. Surgical excision remains the main stay of treatment.
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Familial hypomagnesemia hypercalciuria with nephrocalcinosis: A rare cause of rickets

**Introduction:** Familial hypomagnesemia with hypercalciuria with nephrocalcinosis (FHHNC) is an inherited tubular disorder due to mutation of paracellin-1, characterized by renal magnesium and calcium wasting, nephrocalcinosis, progressive renal failure and ocular abnormalities. This syndrome is also associated with the development of rickets in \~10-15% of cases. Case Report: A 16-year-old female, born of consanguinity, was referred for evaluation of rickets. Since 2 years the patient c/o diffuse bone pains with progressive proximal muscle weakness. There was h/o polyuria, but no h/s/o nephrolithiasis/urinary tract infections. Family history was negative. O/E the patient\'s height and weight were \<3^rd^ centile. She had genu varum, wrist widening and mild frontal bossing. Biochemical evaluation revealed normal electrolytes, e-glomerular filtration rate (Shwartz) of 64, normal phosphorus and corrected calcium varying from 6 to 7.8 mg/dl, but with significant calciuria (9 mg/kg/day). There was no phosphaturia, glycosuria or proteinuria. Arterial blood gas revealed normal anion gap metabolic acidosis with urine pH of 6.5 s/o distal renal tubular acidosis, but urine pH reduced to five on fludrocortisone-furosemide test. US abdomen showed bilateral nephrocalcinosis. Her parathyroid hormone was 216 pg/ml with a 25-hydroxy vitamin D of 12 ng/ml. This unique biochemical profile was suggestive of FHHNC and in concordance with that her magnesium level was 0.7 mg/dl with FeMG of 52%. Patient was started on calcium and magnesium supplements along with thiazides and citrate.

**Discussion:** The causes of nephrocalcinosis are traditionally separated into three groups : Hypercalcemic-hypercalciuric, normocalcemic-hypercalciuria and normocalcemic-normocalcemic. FHHNC is usually considered under the normocalcemic-hypercalciuric variety. In a case series of 30 patients, this syndrome was associated with hypocalcemia in \~20% of the cases (probably due to concomitant vitamin D deficiency) and rickets in 15%. The measurement of magnesium levels in warranted in cases of rickets especially with associated nephrocalcinosis.

**Key words:** Hypercalciuria, hypocalcemia, hypomagnesemia, nephrocalcinosis, rickets
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**Objective:** Case series of primary hyperparathyroidism due to mutation in the HRPT2 gene.

**Patients and Methods:** Four families with primary hyperparathyroidism associated with either polycystic kidneys or ossifying jaw tumor or family history of hyperparathyroidism are presented in this case series.

**Results:** The results show four families with primary hyperparathyroidism with genetic analysis suggestive of mutations in the HRPT2 gene.

**Conclusion:** HRPT2 mutations should be considered as a cause for hyperparathyroidism in patients presenting at the young age, with family history or with associated features like polycystic kidneys or ossifying jaw tumors.

**Key words:** HRPT2 hyperparathyroidism
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**Context:** Tumor induced osteomalacia (TIO) is a disabling phosphate wasting disease, which offers the chance of complete cure if the lesion could be identified and removed. We present a series of four patients of TIO who underwent radio frequency ablation (RFA) of the culprit lesions as a modality of treatment.

**Objective:** The objective of this study is to determine the efficacy of RFA in TIO.

**Patients and Intervention:** Four patients with TIO were evaluated to confirm the tumor mediated phosphatonin induced phosphate wasting osteomalacia and to localize the culprit lesions on functional and anatomical imaging. Patient A: 40-year-old male with long standing osteomalacia with non-ossifying fibroma of right lower end of femur had undergone bone curettage and grafting as the primary modality of treatment after which he remained uncured with reduced, but persistent requirement for phosphate mixture. He was subjected to RFA (2 sittings at present) as the repeat surgery carried a high risk of the need for amputation. Patient B: A 38-year-old male with TIO with the lesion in the head of right femur subjected to 1 sitting of RFA. Patient C: 22-year-old female with the lesion in the roof of right acetabulum underwent single sitting of RFA. Patient D: 28-year-old female with the lesion in the proximal shaft of the left femur subjected to single sitting of RFA.

**Outcome:** The post RFA outcomes were measured in terms of symptomatic improvement, serum phosphorus normalization and reduction in requirement of phosphate mixture.

**Results:** Out of the four patients undergoing RFA, complete cure was demonstrated in two patients (patient B and D) with more than 80% improvement in symptoms (within a week) normalization of serum phosphorus (on day 7) and complete cessation of phosphate mixture. However in patient C, the RFA of lesion in the roof of the right acetabulum did not result in improvement in any of these measures and she was subjected to surgical excision, which resulted in complete cure. Patient A had a larger non ossifying fibroma of the lower end of the femur. Hence, he was subjected to multiple sittings of RFA (currently 2) with significant response. Thus, RFA lead to complete cure in two out of four patients, partial improvement in one and no response in one.

**Conclusion:** RFA is an effective, non-invasive modality of treatment in TIO.

**Key words:** Radio frequency ablation, tumor induced osteomalacia
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**Introduction:** Hypothyroidism is one of the most prevalent endocrine diseases. Though the treatment of hypothyroidism is straightforward, data from several studies show that only around 60% of patients on thyroxine replacement have normal thyroid stimulating hormone (TSH) levels. We, therefore, undertook an audit of hypothyroid patients attending a tertiary care center.

**Objectives:** To determine the prevalence of various etiologies causing hypothyroidism. To ascertain the dose of thyroxine required to attain euthyroid status and its determinants.

**Materials and Methods:** A retrospective audit of hypothyroid patients attending the thyroid clinic in Bai Yamunabai Laxman Nair Charitable Hospital, Mumbai (excluding patients with follow up of less than 3 months, pregnancy, thyroid carcinoma, known gastrointestinal (GI) disorders, and medical illness) has been undertaken. Hospital records and clinical evaluation are being used to collect data on various parameters like etiology, frequency of TSH monitoring, recent value of TSH, current weight, and dose of thyroxine.

**Results:** Eighty-one (73 females) patient\'s interviews have been conducted in this ongoing study. Of these patients 69% have autoimmune hypothyroidism (AH), 17.28% have post operative hypothyroidism (POH), 8.64% have post radioactive iodine hypothyroidism (PRH) and 4.93% have congenital hypothyroidism (CH). Euthyroidism and iatrogenic hyperthyroidism were observed in 61.7% and 9.8% cases, respectively. Average dose requirement of thyroxine is 1.53 ±0.35 μg/kg in AH, 1.5 ± 0.41 μg/kg in POH, and 1.5 ± 1.34 μg/kg in PRH. Euthyroid status is better attained in POH (71.42%) as compared to AH (62.5%) and PRH group (57.14%).

**Conclusion:** Autoimmune Hypothyroidism is the commonest etiology of hypothyroidism. Euthyroid status was achieved in 61.7% of overall patients. Adherence to therapy and attainment of euthyroid status is best in POH. Dose requirement is similar across all major etiologies of hypothyroidism. Periodic monitoring is essential to maintain and improve standard of patient care especially of chronic illnesses.

Dose related response to methimazole in patients with Graves' disease
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**Introduction:** Limited number of studies suggests lower Methimazole dose may be effective in achieving euthyroidism. Our study is a prospective randomized trial to compare the response of Graves' disease patients to high and low dose Methimazole.

**Objectives:** To study treatment outcome parameters in patients with Graves' disease with low (10 mg) versus high (20 mg) dose of Methimazole.

**Materials and Methods:** The study was a 6-month prospective open labeled follow up study. Total 40 patients of Graves' disease were selected. Irrespective of the disease activity and age, the patients were randomized to two groups. Nineteen patients in high dose group received Methimazole 20 mg and 21 patients in low dose group received 10 mg. Patients were followed up at 6 weeks, 3 months, and 6 months. Thyroid function tests were done at baseline and follow-up visits.

**Results:** Were compared with clinical parameters. RESULTS: The high dose group had significantly low total thyroxine (T4) at 6 weeks (104 ± 2.24 Vs 154 ± 2.46 nmol/l), 3 months (86 ± 2.46 Vs. 126 ± 2.22 nmol/l, *P* \< 0.001), and 6 months (68 ± 2.28 vs. 104 ± 2.38 nmol/l, *P* \< 0.001)). Total Triiodothyronine (T3) (2.18 ± 0.82 Vs 3.04 ± 0.42, 1.74 ± 0.56 Vs. 2.24 ± 0.46, 1.54 ± 0.42 Vs. 2.02 ± 0.36 nmol/l, *P* \< 0.001) also showed similar pattern. Six cases (31%) developed hypothyroidism in high dose group. Clinical symptoms of thyrotoxicosis resolved whereas opthalmopathy and goiter size did not change with treatment at the end of 6 months. No treatment related adverse effect was seen.

**Discussion:** Low dose of 10 mg Methimazole is effective in achieving euthyroidism without developing hypothyroidism. Both groups achieved euthyroidism within 6 weeks highlighting the relatively low dose requirement in our patient population. The short duration and small study population must be taken into account during interpretation of results.

**Conclusion:** Low dose of Methimazole 10 mg is effective in treating Graves' disease.

**Key words:** Graves' disease, Methimazole, dose

A descriptive study of thyroid carcinoma patients attending an endocrine clinic in Chennai
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**Background:** Thyroid cancer accounts for 1-3% of all cancers. There is marked increase in the incidence with iodine repletion. New trends seem to be emerging.

**Aims:** To analyze clinical, demographic, pathological, radioisotope, surgical, and other therapeutic data; with a follow-up of the patients.

**Study Design:** Retrospective analysis of medical records of patients attending Endocrinology outpatient (OP) from 2007 to 2012 in a tertiary care hospital in Chennai.

**Results:** In total there were 69 patients with a female preponderance (50 vs 19 males, F:M ratio of 2.5:1). Majority (73.5%) patients were from Chennai, 23.8% from Andhra Pradesh, one (1.5%) from West Bengal, and one from Port Blair (1.5%). The median age at presentation for was 40 years, range 20-83 years. The males presented a little later (median age 45 vs 38 years) than women. The clinical presentation was as a solitary nodule in 46%, nodular goiter in 36%, goiter with lymphadenopathy in 11%, lymphadenopathy in 1.4%, hoarseness in 1.4%, and bone metastases in 2.8%. The diagnosis was confirmed by fine needle aspiration cytology in most (84.1%) of the patients. Papillary carcinoma constituted 59 (85.5%), follicular carcinoma six (9.5%), anaplastic carcinoma two (3%), and medullary carcinoma and lymphoma one each (1.5%). Among those who had papillary carcinoma; 54 had classical, four had follicular variant, and one had a cystic variant. Fifty-four (78%) presented with stage I disease, seven with stage II (10%), one with stage III (1.4%), and seven with stage IV disease (10%). Six patients with papillary carcinoma had an underlying Hashimoto\'s thyroiditis (8.7%). Total thyroidectomy was performed in 60/69 (87%), while the rest underwent a two stage procedure. Majority of patients with stage I/II have been cancer free with a single ablative dose (mean dose of 94.6 mCi for stage I and 134 mCi for stage II differentiated CA). Patients with stage I and nodal metastases required more than one ablative dose. The cystic variant of papillary carcinoma was resistant to RAI131 and had to undergo radiotherapy (RT) + chemotherapy. Out of 69, 15 (21%) had to be recalled as they did not report after initial radioiodine ablation. One patient with advanced papillary carcinoma opted out of chemotherapy as not tolerated. Adjuvant RT was offered to seven patients (10%) and chemotherapy to three (4%).

**Conclusions:** Thyroid carcinoma has shown a similar trend as has been described in the literature. Early age at diagnosis and early staging (I/II) seems to offer a favorable prognosis. Ultrasound imaging would be helpful in detecting early nodules in patients with goiterous thyroiditis.
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Demographic data of thyroiditis from south indian city
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**Background:** Thyroiditis involves thyroid gland inflammation due to a wide variety of causes. The common varieties are subacute, silent, and postpartum thyroiditis.

**Aims and Objectives:** To retrospectively collect demographic data of thyroiditis from Bangalore over the past 5 years.

**Materials and Methods:** Data was collected from five major nuclear medicine centers in Bangalore of the patients who came for Technetium-99m (Tc-99m) pertechnetate scan of the thyroid. The diagnosis was based on the Tc-99m scan evidence of thyroiditis in these patients.

**Results:** The total number of cases recorded were 2513. The females were more commonly affected compared to males with sex distribution of 1530 females vs. 787 males (2:1). The mean age of females was 32.5 ± 11.3 years while the mean age of males was 37.2 ± 12.4 years. The highest numbers of cases were recorded in the month of June and August.

**Conclusions:** The females developed thyroiditis more frequently and at an earlier age as compared to males and it was more common in the months of June and August. This data could give us an insight into the demographic pattern of thyroiditis in our country and may help in planning future preventive strategies.
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Detection of BRAF mutations in different thyroid cancers of archival FNAC samples
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**Introduction:** Early detection of thyroid cancers improves prognosis, quality of patient life, and provides additional treatment options. Fine-needle aspirate cytology (FNAC) is an accurate method diagnosing most PTCs based on classical cytological features. Detection of biomarkers may increase the sensitivity of FNAC for nodules that are indeterminate or suspicious on cytology. The BRAF V600E mutation leads to a constitutively activated MAP kinase signaling pathway and has been implicated in numerous cancers. There are no studies available on its possible role in PTC in an Indian population. Preoperative knowledge of the BRAF mutation may be helpful in planning the degree of surgical treatment for patients, particularly if BRAF V600E is shown to be a negative prognostic factor.

**Objectives:** (1) To study BRAF V600E gene mutations as a potential marker to differentiate thyroid cancers of archival thyroid FNAC samples.

**Materials and Method:** DNA was extracted from Archival FNAC slides and mutation analysis by PCR amplification and sequencing.

**Results:** Isolated DNA from FNAC slides of 40 thyroid patients (2009-2012) was PCR amplified and analyzed by sequencing. Amplification was effective in 28 slides due to poor DNA yield from archival slides. The 28 samples were grouped as 17 papillary thyroid; 4 follicular variant; 3 follicular; 1 Hurthle cell; 3 follicular adenoma and 0 medullary respectively. The BRAFV600E mutation was observed in two patients exclusively in the papillary thyroid carcinomas and not in any other group. This pilot study shows that the mutation was present in at least 12 % of patients with PTC alone.

**Conclusion:** This pilot study indicated the presence of the BRAFV600E mutation in FNAC samples of 12% of patients with papillary thyroid carcinoma in a small group of a mixed south Indian population around the Chennai city area. The study confirms our ability to preoperatively measure BRAF in FNAC samples. The study needs to be expanded to a larger sample size. We plan to analyze other relevant thyroid mutations such as, KRAS, and RET/PTC in a prospective manner.

**Key words:** Archival FNA, BRAF V600E, PTC
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**Background:** The outcome of I^131^ radioiodine therapy in patients with Grave\'s disease is influenced by several variables. Antithyroid medications (ATD) have been shown to attenuate the effectiveness of radioiodine therapy. We undertook a study to look at the impact of iodine uptakes on the outcome of I^131^ therapy in a population in Tamil Nadu where iodized salt is universally available.

**Objectives:** To determine the effect of radioiodine uptake and ATD on the duration of time to achieve cure (TC) in patients who received a fixed dose (15 mCi) of I^131^ radioiodine for Grave\'s thyrotoxicosis.

**Materials and Methods:** The study examined 453 patients with Grave\'s disease, who underwent radioiodine ablation from January 2010 to December 2012 and followed-up on a 2-monthly basis with thyroid stimulating hormone (TSH), free triiodothyronine (T3), and free thyroxine (T4) levels. One hundred and nineteen patients, who gave informed verbal consent to access their records, had a documented preablation radioiodine uptake and consistent follow-up in our medical center were included in the final analysis. All patients received a fixed dose of 15 mCi I^131^. Thirty-eight subjects (32%) had lower nonsuppressed radioiodine uptake (10-35%) and 81 subjects (68%) had a distinctly increased uptake (\>35%). Cure was defined as the elimination of thyrotoxicosis in the form of low free T4 and rising TSH levels.

**Results:** An overall cure rate of 93% was observed after a single dose. The average time to cure (TC) was 193 days. Surprisingly, a directly proportional linear relationship (R^2^ coefficient = 0.92) was observed between TC and radioiodine uptake (TC~\>35%~= 231 days, TC~10-35%~= 110 days, *P* \< 0.05). As expected, patients who used ATD took a longer time to achieve remission (TC~NO\ ATD~= 112 days, TC~ATD~= 292 days, *P* \< 0.05). The effect of ATD therapy in delaying remission was amplified in the subset of patients with higher uptakes (TC~\>35%+ATD~= 366 days, TC~\>35%+NO\ ATD~= 116 days, *P* \< 0.05) compared to those with the lower nonsuppressed uptakes (TC~10--35%+ATD~= 121 days, TC~10--35%+NO\ ATD~= 103 days, *P* \< 0.05).

**Conclusion:** I^131^ radioiodine ablation, using a fixed dose of 15 mCi achieved a high cure rate. In a population using iodized salt, higher uptakes predicted longer time to remission, with prior ATD use amplifying this effect.

**Key words:** Anti-thryoid drugs, grave\'s disease, radioiodine ablation

Hashimoto\'s encephalopathy presenting with multiple cranial nerve palsies and hemiparesis: A case report

Arijit Singha, Santanu Saha, Riddhi Dasgupta, Adreesh Mukherjee, Dhiman Das, M. K. Roy

**Introduction:** Hashimoto\'s encephalopathy is a steroid responsive encephalopathy associated with elevated concentration of antithyroid antibodies. The patients are usually euthyroid or hypothyroid. A wide array of clinical features has been reported till date. The pleomorphic manifestations may be behavioral or cognitive changes, myoclonus, pyramidal tract dysfunction, coma with relapsing, and pogressive course. The diagnosis is often overlooked at presentation given that this is a treatable disease.

**Description of Case:** A 32-year-old male nondiabetic, nonhypertensive, nonalcoholic, and nonsmoker presented to us with sudden onset right sided hemiparesis and deviation of angle of mouth to left. This episode was preceeded by hoarseness of voice and difficulty in swallowing for 1 week. On examination patient was confused with slurred speech. There was right sided hemiparesis, power 3/5 in right upper and lower limb, exaggerated deep tendon reflex in all four limbs, extensor plantar response in right side along with lower motor neuron type palsy of right 7^th^, 9^th^, 10^th^, and 8^th^ cranial nerve palsy. All routine examinations were normal including magnetic resonance imaging (MRI) of brain, electroencephalogram (EEG), and cerebrospinal fluid (CSF) study. But anti-thyroid peroxidase (TPO) was high (\>1,300 U/L) with normal serum free thyroxine (FT4) and thyroid stimulating hormone (TSH). Ultrasonography (USG) revealed heterogenous thyroid and fine needle aspiration cytology (FNAC) showed lymphocytic autoimmune thyroiditis. We started steroid and in follow up patient experienced significant improvement.

**Discussion:** Hashimoto\'s encephalopathy is an unusal neurological disorder with myriad of clinical features. Elevated serum antithyroid antibodies remains an essential characteristics of diagnosis. The pathogenic role of antbodies remains obscure.

**Conclusion:** This is a first reported case of multiple cranial nerve involvement in a case of Hashimoto\'s encephalopathy. Henceforth, this presentation if kept in mind might help in instituting correct and early treatment.

**Key words:** Cranial nerve palsies, hashimoto encephalopathy

Multicenter program for newborn screening for congenital hypothyroidism -- Experience with cord blood versus postnatal heel prick
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**Introduction:** In India, newborn screening (NBS) is not yet a national government policy. Incidences of congenital hypothyroidism (CH), recall cut off and recall rates are not clear for our population.

**Objectives:** To evaluate the feasibility and recall rates in NBS program for CH in an underprivileged population in India.

**Materials and Methods:** Postnatal (PN)-NBS and CB-NBS samples were collected on Whatman 903 filter paper. In PN-NBS, babies with screen thyroid stimulating hormone (TSH) \> 20 μU/ml were recalled for repeat filter paper sample at 12-14 days of age. Screen TSH \> 40 μU/ml resulted in immediate recall for venous serum thyroxine (T4) and TSH. After the first 6,500 babies, we applied age related cut offs, of 34 μU/ml for age at sampling 24-48 h and 20 μU/ml thereafter. Dried blood spot TSH assay by immunofluorometry (Perkins Elmer) had a sensitivity of 4.4 μU/ml serum units. For CB-NBS, we applied cut off of TSH \> 40 μU/L for recall for venous serum sample.

**Results and Discussion:** PN-NBS after 24 h of birth was carried out in 13,500 babies. Recall rate was 1.3%, applying fixed cut offs. Using age related cut offs, recall rate was 0.74%. CB-NBS was carried out in 4,200 babies and our recall rate was 0.66%. Eleven babies were detected CH by postnatal (PN) screening and one baby by cord blood (CB) screening. Of these, 10 had permanent CH (six with dyshormonogenesis) and two had transient CH. Eleven babies are in follow-up at 1 year age. Median urinary iodine in 350 mothers was 189 μg/l. Insufficient urinary iodine levels (\<150 μg/l) was present in 42% women. We found no correlation of urinary iodine with cord or PN TSH. TSH \> 10 μU/ml (serum) after 48 h was 6%, that is, consistent with mild iodine deificiency disorder (IDD (World Health Organization, WHO)).

**Conclusion:** Age related cut offs are needed to deal with high recall rate and early discharge. Iodine deficiency may be one contributory factor for high recall rate.

**Key words:** Cord blood, congenital hypothyroidism, newborn screening

Thyroid function abnormalities in patients with juvenile onset type 1 diabetes
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**Objective:** Thyroid function abnormalities are frequently described in patients with type 1 diabetes mellitus (T1DM). The objective of our study was to estimate the prevalence of thyroid function abnormalities in juvenile onset Type 1 diabetics (T1D) in comparison with sex matched healthy controls.

**Materials and Methods:** For this study, 88 patients who were below 18 years of age were diagnosed with diabetes, according to American Diabetes Association (ADA) criteria and classified as T1D on clinical grounds were recruited. Sex-matched healthy non-diabetic controls aged 2-18 years (*n* = 88) were also recruited. Free T3, free T4 and thyroid stimulating hormone (TSH) were measured by the enzyme-linked immunosorbent assay.

**Statistics:** Normality of the data was assessed by Shapiro-Wilk test. Student\'s *t*-test, Mann-Whitney\'s U-test and Chi-square test were used to compare results between two groups.

**Results:** The prevalence of thyroid dysfunction was 11.4% in patients and 5.7% in controls. Free T3 and free T4 values were significantly lower in patients as compared with controls. Difference in TSH value between two groups was not statistically significant although patients had higher TSH. Seven patients had hypothyroidism compared with two controls, both of which had subclinical hypothyroidism. In each group, three subjects had subclinical thyrotoxicosis.

**Discussion:** The ADA recommends screening for thyroid disease on an annual basis using a serum TSH. Our results support the need to screen for thyroid dysfunction in T1D patients. Significantly, lower free T3 and free T4 values in patients compared with controls may signify the presence of subclinical hypothyroidism in a larger extent than otherwise recognized.

**Conclusions:** Our results suggest a high prevalence of thyroid dysfunction in patients with T1DM. Children and adolescents with T1DM should be routinely screened for thyroid dysfunction.

**Key words:** Thyroid dysfunction, type 1 diabetes mellitus

Pancreas and Diabetes: Clinical profile of patients using normal, high and very high insulin doses in type 2 diabetes
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**Introduction:** Insulin requirement varies between patients with diabetes due to insulin resistance. The profile of patients based on their insulin requirement has not been studied.

**Objective:** We stratified the patients based on the total daily insulin requirement (TDIR) and studied their clinical profile and dietary consumption patterns.

**Materials and Methods:** A total of 60 patients with type 2 diabetes (aged 30-75 years, using stable insulin dose for last 6 months, hemoglobin A1c between 6% and 7.5%, negative screening tests for Acromegaly and Cushing\'s disease) participated in this clinical observational study. All patients with a major illness, recent surgery, diabetic ketoacidosis, post-transplant diabetes and lipodystrophy were excluded. Patients were divided into 3 groups: Group 1 (TDIR \<1 U/kg, *n* = 30), Group 2 (TDIR 1-2 U/kg, *n* = 20) and Group 3 (TDIR \>2 U/kg, *n* = 10). Appropriate statistical methods were used for comparison between groups.

**Results:** Patients (27 F:32 M) had a mean age 54.3 ± 12.3 year, diabetes duration 10.1 ± 4.7 year and an A1c of 7 ± 0.38%. Patients in Group 3 had a lower body weight, body mass index and the highest carbohydrate consumption when compared with the other two groups (*P* \< 0.05). Hypoglycemic episodes and complications did not differ between the groups.

**Conclusions:** Our data showed that the low body weight and high carbohydrate intake are associated with increased insulin requirement. The clinical implications of our study are to check the carbohydrate intake in patients with the high insulin requirement.

**Key words:** High insulin requirement, insulin dose, insulin resistance, type 2 diabetes

Concerns about hypoglycemia in India: Results from second diabetes attitudes wishes and needs study
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**Introduction:** The second diabetes attitudes wishes and needs (DAWN2) study is a multinational observational study, which took place in 17 countries including India, and aimed to provide a holistic assessment of diabetes care and management among people with diabetes (PWD), family members (FM), and healthcare professionals (HCPs). It explored potential drivers leading to active management of diabetes and assessed barriers to the same. Hypoglycemia is an inevitable complication and barrier to tight glycemic control in patients with diabetes.

**Objectives:** This abstract describes the frequency and type of hypoglycemic episodes among PWD, and concerns regarding hypoglycemia among PWD, FM and HCP, in the Indian cohort of DAWN2.

**Materials and Methods:** DAWN used a cross-sectional study design to collect different aspects of diabetes care. Information about hypoglycemia in DAWN2 study was analyzed from randomly chosen Indian subjects, and collected by questionnaires from face to face interviews with PWD, HCP and FM. Descriptive statistics were used to report the data.

**Results:** All qualified PWD were analyzed according to these subgroups: (T1 \[type 1 diabetes\]: *n* = 78; T2 non-med \[type 2 diabetes not on medication\]: *n* = 100; T2 non-insulin med \[type 2 diabetes on medications other than insulin\]: *n* = 170 and T2 insulin med \[type 2 diabetes on insulin with or without medication\]: *n* = 152) were included in the analysis. Among persons with T1 diabetes, 41% reported self-treated episodes of hypoglycemia in a frequency of less than 1 per month compared, to 49% with T2 diabetes on insulin. 29% people with T1 diabetes reported similar self-treated episodes several types per month (or once a week) compared to 17% in T2 diabetes on insulin. The mean frequency of severe hypoglycemia in last 12 months among these PWD was as follows: T1 diabetes: 2.2, T2 non-med: 2.6, T2 non-insulin med: 2.4 and T2 insulin med: 3.2. Roughly one-quarter of T1 PWD (26%) and one-third of T2 insulin med PWD (32%) reported that they could often or always tell by their symptoms that their blood sugar is low. About one-quarter of FMs (22-26%) reported that the person they live with had low blood sugar symptoms at least once a week or several times a month. FMs insulin med indicated that the person they live with has had on average 2.3 severe low blood sugar episodes in the past 12 months. One-third of FMs insulin med (32%) were also able to often or always recognize by the symptoms that the person they live with is having a low blood sugar episode. More than one-quarter of FMs felt they have to help with low blood sugar events at least once a week or several times a month (27-28%) whereas, between 25% and 32% of FMs only feel that they are at the best somewhat confident of dealing with these type episodes.

**Conclusion:** Around one-third of Indians with type 1 diabetes experienced self-reported episodes of hypoglycemia several times a month (or more than once a week). Only a third of FM of persons with diabetes could recognize symptoms of hypoglycemia. Only a third of FM of patients with diabetes felt they were only somewhat confident of dealing with hypoglycemic episodes. This highlights a major lacuna in existing insulin therapy, in diabetes education of both PWD and FM, in hypoglycemia awareness training, and in self-management of hypoglycemia in India. Necessary skills need to be imparted to all stake holders in diabetes care.

Quality of life of people with diabetes: Second diabetes attitudes wishes and needs (DAWN2) study-Indian cohort
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**Background:** Diabetes Mellitus (DM) is a major public health problem in India with International Diabetes Federation estimating around 61.3 million people with diabetes in 2011. This figure is projected to rise to 101.2 million by 2030. Literature from western settings has consistently found a significant association between DM and impaired quality of life (QoL). However, such literature is limited from Indian settings.

**Aim:** The current study (Second Diabetes Attitudes Wishes and Needs (DAWN 2)) aimed at assessment of potential barriers to and facilitators of active and successful management of diabetes among people with diabetes, family members, and healthcare professionals. QoL was one of the variables included in this study.

**Methodology:** The quantitative survey of 500 people with diabetes (PWD) was conducted across India in cities of Delhi, Mumbai, Kanpur, Chennai, Hyderabad, Bangalore, and Kolkata. Data was collected between June 23 and August 23, 2012. Participants were recruited through clinic and hospital intercepts like proprietary databases, patient organizations, diabetes associations, and physician referrals. Instrument used included sociodemographic proforma, WHO QoL BREF, EuroQoL (EQ-5D), WHO Well Being Index (WHO-5). The comparisons were made between four groups viz. type I DM (group I), type II DM without any medication (group II), type II DM on treatment with medications other than insulin (group III), and type II DM on insulin (group IV).

**Results:** A total of 500 subjects were included in the study. All the groups have comparable proportion of males and females except for the group II that had 65% males. Mean age of diagnosis of DM was 26.0, 42.9, 45.5, and 48.5 years for groups I, II, II, and IV; respectively. QoL, as assessed by WHO QoL BREF, was reported to be good/very good by 59% of individuals in group II. This was significantly higher than other three groups. Also, overall a significantly greater proportion of males (50%) reported the QoL to be good/very good as compared to females. The proportion of individuals reporting the QoL to be good/very good was highest (61%) for individuals with no associated physical/psychological condition. Globally, Denmark ranked first on this indicator and Algeria ranked last. India ranked ninth among the countries. The proportion was lowest for those with both physical and psychological conditions (30%). EQ-5D score was highest (87) for Group II and lowest for Group I. EQ-5D-Visual Analog Scale score was also highest (74) for Group II and lowest (62) for Group I. India ranked eighth on this variable. The list was topped by China. Good well-being was reported by 81% each respondents in Group II and III on WHO-5 Well Being Index. This proportion was comparable for males and females. India ranked third overall, with Mexico topping the list.

**Conclusions:** The QoL of people with diabetes is impaired and it is recommended to take appropriate measures to address it.

**Key words:** Diabetes, quality of life

Prevalence of Vitamin D deficiency in pregnancy and its correlation with the development of gestational diabetes mellitus
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**Introduction:** Vitamin D (VitD) deficiency is highly prevalent in India. VitD deficiency during pregnancy causes impaired insulin release and insulin resistance due to VitD receptors in the pancreatic beta cells and peripheral tissues. Association of VitD deficiency and Gestational diabetes mellitus (GDM) is controversial.

**Objectives:** To determine the prevalence of GDM in the ante-natal clinic of a tertiary care center. To correlate VitD deficiency in the first half of pregnancy with the development of GDM.

**Materials and Methods:** Consecutive subjects registering at the antenatal clinic were recruited for this study (excluding those with known diabetes mellitus and on diabetogenic medications). They underwent VitD estimation, homeostasis model of assessment-insulin resistance (HOMA-IR) measurement in first half and 75 gm *oral glucose tolerance test* (OGTT) at 26-28 weeks of pregnancy. GDM and gestational glucose intolerance (GGI) were defined as per Diabetes In Pregnancy Study group India (DIPSI) criteria. Thirty-eight women with GDM and GGI and thirty- eight age and parity matched controls were selected for subgroup analysis. VitD deficiency and insufficiency were defined as VitD \< 20 ng/ml and 20-30 ng/ml, respectively.

**Results:** The prevalence of GDM and GGI was 7.27% and 27.27%, respectively. Ninety-two percent had deficient and 5% had insufficient VitD levels. The mean serum 25-hydroxy vitamin D (25(OH) D) levels in the GDM/GGI and non GDM group were 10.7 ± 7.5 ng/ml and 8.6 ± 6.4 ng/ml, respectively. There was a strong negative correlation between VitD values and HOMA-IR with *P* = 0.055. No correlation between VitD levels and fasting and 2 hours OGTT blood glucose values was found.

**Conclusions:** VitD deficiency is highly prevalent in pregnant women. There is a strong negative correlation between VitD values and HOMA IR, which did not translate in the development of GDM/GGI. No significant difference was found between VitD levels of the GDM/GGI and non GDM group.

**Key words:** Gestational diabetes mellitus, gestational glucose intolerance, homeostasis model of assessment-insulin resistance, Vitamin D deficiency

Clinical characteristics, risk factors, bacteriology, and treatment outcome of diabetic foot ulcer: Study from a tertiary care center

M. S. Raghu, Dipti Sarma, Uma Kaimal Saikia, Bipul Kumar Choudhury

Department of Endocrinology, Gauhati Medical College, Guwahati, Assam, India

**Corresponding Author:** *Dr. M. S. Raghu, Department of Endocrinology, Gauhati Medical College, Bhangagarh, Guwahati - 781 032, Assam, India. E-mail: dr.msraghu\@gmail.com*

**Introduction:** Diabetic foot ulcer is one of the most feared complications of diabetes and is associated with more morbidity. Diabetes patients have a life-time risk as high as 25% for developing foot ulceration and it is the most common cause of non-traumatic amputation.

**Objectives:** This study was undertaken to determine the clinical characteristics, risk factors, bacteriology, and outcome of diabetic foot ulcer.

**Materials and Methods:** A prospective study was conducted from April 2012-March 2013 in endocrinology department of Gauhati Medical College, Assam. Forty cases of diabetic foot ulcer patients underwent detailed history, clinical examination, laboratory examination including microbiological culture and sensitivity.

**Results:** Among 40 cases, 31 were males (77.5%) and 9 (22.5%) were females. The mean age of cases was 55.2 ± 10.2 years. The mean duration of diabetes was 7.2 ± 5.5 years. Most of the cases had poor glycemic control (mean HbA1c 10.6% ± 2.5). Most of our cases had Wagner\'s grade II ulcer (72.5%), grade III (17.5%) and grade IV (10%). The most common risk factors for diabetic foot ulcers were lack of foot care knowledge (82.5%), peripheral neuropathy (77.5%), hypertension (60%), and smoking (52.5%). Out of 40 cases, 67.5% had monomicrobial infection, 27.5% had polymicrobial infection and 8% were culture negative. In our study, gram positive (57.6%) bacterial infections were predominant than gram negative (42.8%); among which *Staphylococcus aureus* was the common bacteria isolated. Six (15%) patients who underwent amputation had grade III and IV ulcer along with polymicrobial infection.

**Conclusions:** In our study, most common risk factors for diabetic foot ulcer were lack of foot care knowledge, peripheral neuropathy, hypertension, and spontaneous blisters. Cases with higher grade of ulcer had longer hospital stay and high risk of amputation. Hence, providing proper foot care education, good glycemic control, early and aggressive management of diabetic foot ulcer will reduce the morbidity associated with diabetic foot ulcer.

**Key words:** Diabetic foot ulcer, Wagner\'s grade, Staphylococcus aureus.

Assessment of metabolic characteristics and body composition in Asian Indian subjects with type 1 diabetes mellitus using euglycemic hyperinsulinemic pancreatic clamp, dual energy X-ray absorptiometry scan and
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**Introduction:** Type 1 diabetes mellitus has a significant contribution to the global diabetes epidemic. However, the physiological mechanisms regulating insulin sensitivity and body composition in them remains elusive.

**Materials and Methods:** A total of 14 male subjects with type 1 diabetes mellitus were studied. Insulin sensitivity at the hepatic and peripheral tissues was evaluated using a 6-h euglycemic hyperinsulinemic pancreatic clamp. Body composition assessment included skin fold thickness, dual-energy X-ray absorptiometry scan for total body fat % and ^1^H-nuclear magnetic resonance spectroscopy for hepatic fat content, intramyocellular lipid (IMCL) and extramyocellular lipid (EMCL) at the level of soleus muscle. The results were compared with nine subjects with type 2 diabetes mellitus and four age and body mass index (BMI)-matched non-diabetic subjects.

**Results and Analysis:** The M value, an index of insulin sensitivity, was lower for subjects with type 1 diabetes as compared with the non-diabetic group (13.82 vs. 22.28 μmol/kg/min). The rate of disappearance of glucose (Rd), an estimate of peripheral insulin sensitivity, was higher in type 1 diabetes subjects as compared with those with type 2 diabetes (8.23 vs. 4.60 mg/kg/min). Endogenous glucose production (EGP), an index of hepatic insulin sensitivity, was similar in type 1 and type 2 diabetes subjects (0.42 vs. 0.43 mg/kg/min). In the type 1 diabetes group, M value correlated significantly with weight, BMI and subscapular skinfold thickness (*P* \< 0.05), Rd correlated with M value, BMI, waist circumference, subscapular skinfold thickness and total body fat % (*P* \< 0.05) while EGP correlated significantly with low-density lipoprotein levels (*P* = 0.01). The IMCL correlated with age, weight, body surface area and hip circumference while EMCL correlated with waist hip ratio and basal metabolic rate (*P* \< 0.05).

**Conclusions:** Subjects with type 1 diabetes were insulin resistant as compared with matched non-diabetic subjects and as insulin resistant at the hepatic level as subjects with type 2 diabetes. IMCL and EMCL were markers for subcutaneous and visceral fat respectively in these subjects.

**Key words:** Body, clamp, composition, euglycemic, hyperinsulinemic

Methodology and rational for a non-interventional study to evaluate diabetes related quality of life, frequency and impact of hypoglycemia in type 2 diabetes patients on pharmacotherapy: Insight study
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**Background:** Many Indian diabetic patients have coexisting hypertension and obesity which predisposes them to a higher cardiovascular risk. This warrants stringent glycemic control, which makes the patients prone to hypoglycemia and glycemic control could be compromised, leading to weight gain and decreased quality of life (QoL). Hence, there is a need for a study to assess the QoL in diabetic patients on various antidiabetic drugs, the frequency and impact of hypoglycemia in relation to HbA1c control and comorbid conditions like hypertension and obesity.

**Objectives:** The primary objective of this study is to assess the diabetes related QoL (DQoL) in type 2 diabetes mellitus (T2DM) patients on pharmacotherapy. The secondary objectives of this study are to assess the frequency and impact of hypoglycemia in relation to HbA1c control with current therapies and to assess the disease modifying variables.

**Research Design and Methodology:** INSIGHT Study is a non-interventional, cross sectional, multicentric study to assess the diabetes related quality of life (DQoL) in T2DM patients on diverse pharmacotherapies (oral/injectable antidiabetic drugs with/without insulin therapy). This study was conducted at 251 sites from 19 states across India, involving 4,967 patients between 16 March 2012 and 20 February 2013. Adult male and female patients with T2DM of more than a year\'s duration and whose treatment remained unchanged in the 3 months prior to the study visit were enrolled into the study. Data include sociodemographics, medical, medication history, and lifestyle patterns with respect to diet and exercise and details of clinical examination, including measurement of height, weight, blood pressure (BP), and HbA1c to determine glycemic control. Statistical analysis is underway.

**Conclusions:** This study will assess the diabetes related quality of life in T2DM patients on pharmacotherapy; evaluate the frequency and impact of hypoglycemia with current therapies, and highlight incidence of disease modifying variables such as body mass index (BMI) and BP.

**Key words:** Diabetes, hypertension, hypoglycemia, obesity

Efficacy of high molecular weight sodium hyaluronate in frozen shoulder in diabetes mellitus type 2 patients: A randomized controlled study
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**Aims and Objectives:** (1). To assess the efficacy of intra-articular injection of high molecular weight sodium hyaluronate (SH) on functional outcome in frozen shoulder in diabetes mellitus (DM) type 2 patients, and (2). To compare it with the efficacy of corticosteroid (methylprednisolone).

**Materials and Methods:** This prospective, double blind, RCT included 67 patients. They were randomized in two groups: Group-A (methyl-prednisolone) and Group-B (SH). Three-weekly intra-articular injections of respective drugs (preceded by intra-articular injection of xylocaine as local anesthetic) were given by posterior technique under ultrasound guidance. Sixty-one patients completed treatment and follow-up. Quick DASH score, total shoulder flexion, and total shoulder abduction (passive) were used for assessment of outcome. Follow-up period was 6 months.

**Result and Conclusion:** Both SH and corticosteroid caused significant improvement in shoulder function beginning within 1 week and lasting for at least 6 months. No significant adverse effects were observed in SH group. Corticosteroid group had 10% incidence of moderate to severe pain in GH joint lasting 12-24 hours. Intra-articular corticosteroid has known adverse effects like worsened glycemic control, osteoporosis, tendon rupture, and decreased immunity at local site. Hence, we suggest that SH may be used as an alternative drug to popular steroid use for the patients of frozen shoulder in DM type 2.

**Key words:** Adhesive capsulitis, diabetes mellitus, frozen shoulder, hyaluronate, periarthritis, steroid

Adrenal: Adrenocortical carcinoma with concomitant secretion of glucocorticoid, androgens, and aldosterone: A rare case
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**Introduction:** Adrenocortical carcinoma (ACC) is a rare tumor with estimated incidence of one per 1 million population per year in adults. Usual age of onset is 40-50 years. Eighty-five percent of tumors are functional, most commonly secreting glucocorticoids alone (45%), glucocorticoids and androgens (45%), or androgens alone (10%). Fewer than 1% of all tumors secrete aldosterone. We present a case of ACC which was secreting all these three hormones and a much younger age of onset (22 years).

**The Case:** A 22-year-old male patient presented with pain abdomen, low grade fever, and painful gynecomastia for last 6 months. On examination he had blood pressure (BP) 170/100, plethoric face, and bilateral (B/L) tender gynecomastia. Routine blood examination revealed Na-142 meq/l and K-1.5 meq/L. Ultrasonography (USG) abdomen done to evaluate pain abdomen showed right adrenal hypoechoic SOL of 10.6--9.5 cm. His serum cortisol was 23.70 μg/dl after 1 mg overnight dexamethasone suppression test (DST) and dehydroepiandrosterone (DHEAS) was 870.50 μg/dl (167.9-591.9), estradiol 60 pg/ml (\<20 pg/ml) and urinary metanephrine 50 μg/24 h. On subsequent evaluation, showed he had high plasma aldosterone and suppressed plasma renin activity (PRA) and high plasma aldosterone concentration (PAC) to PRA (PAC/PRA) ratio (53.50). CT abdomen revealed right adrenal heterogenous SOL with density 31 Hu (noncontrast) and post contrast 43 Hu with contrast washout \<55%. Fine needle aspiration (FNA) and excisional biopsy showed features suggestive of ACC.

**Discussion:** Concomitant secretion of glucocorticoid, androgens, and aldosterone as evidenced by increased level of morning cortisol after 1 mg overnight DST, increased level of DEHAS, and high plasma aldosterone and suppressed PRA and high PAC/PRA ratio in a young patient with ACC is very rare. Only a few cases have been reported previously.

**Key words:** Adrenocortical carcinoma, aldosterone, androgens, glucocorticoid

Atypical fracture of femur in multiple myeloma patient on high dose zoledronic acid: A case report
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**Introduction:** Atypical fractures of the femur below the lesser trochanter have been reported in patients treated with bisphosphonates.

**Description of the Case:** A 69-year-old woman presented with spontaneous, acute onset, severe deep aching pain in the left upper thigh and history of fall thereafter in the dining area. However, she did not recall any significant trauma. She had been diagnosed with multiple myeloma 7 years back and managed with thalidomide, cyclophosphamide, and dexamethasone based chemotherapy; and subsequently underwent autologous stem cell transplantation. She was also given bisphosphonate therapy in form of intravenous (IV) zoledronic acid (ZA) 4 mg per month regularly since last 7 years. Radiographs demonstrated transverse femoral shaft fracture with thickening of the lateral cortex and medial cortical spike at the site of fracture. The contralateral femur also showed thickening of the lateral cortex at the same site. She underwent open reduction and internal fixation with intramedullary nailing and screw fixation. On follow-up 3 months later, her fracture was completely healed. ZA was then stopped.

**Discussion:** This type of atypical fracture is related to severe suppression of bone turnover (SSBT) under bisphosphonate therapy. The fracture in our patient was considered to be related to SSBT under prolonged high dose ZA therapy. Doses of ZA recommended for cancer patients are much greater than those for patients with osteoporosis. The risk/benefit ratio of bisphosphonates has been documented in multiple good quality studies. Even so, caution should be used before continuing therapy for \>5 years, and prodromal symptoms should be taken into consideration. These atypical fractures should preferably be managed with internal fixation.

**Conclusions:** High dose prolonged ZA therapy may lead to atypical fracture of femur below lesser trochanter in small fraction of patients.
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Long-term follow-up of patients with hirsutism: A case series
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**Objectives:** The objective of this study is to assess the therapeutic outcome in patients with hirsutism treated by metformin, aldactone, cyproterone acetate or oral contraceptive pill (OCP) either alone or in various combinations.

**Design:** Retrospective analysis was performed of patients with hirsutism, referred to the endocrine clinic of our hospital which is a tertiary care referral center. Of the total 75 such women, those with more than 30 months follow-up were included in the present study. Anthropometric, clinical, biochemical and hormonal profiles of patients were analyzed. Various therapeutic regimes and the number of patients in each group were recorded and analyzed for any relation with final outcome. The treatment outcomes were measured in terms of improvement in Ferriman Gallwey hirsutism score, reduction in requirement of cosmetic measures and associated benefits, e.g., menstrual cycle regularity and conception.

**Results:** A total of 30 patients had more than 30 months follow-up. Their mean age was 19.33 years (36-11 years) and mean body mass index was 25.346 kg/m^2^. Twenty (66.67%) showed clinical improvement in terms of measured outcomes. 5 (25%) of them were on single drug while 15 (75%) were on combination therapy; 13 (65%) were on metformin either alone or in combination with cyproterone acetate/OCP/aldactone and 11 (55%) were on aldactone either alone or in combination with cyproterone acetate/OCP/metformin. Improved clinical outcomes and better compliance were noted in patients treated with combination of drugs.

**Conclusion:** Combination of more than one drugs including metformin, aldactone, OCP, cyproterone acetate is more effective than single drug the treatment of hirsutism. Compliance and cost of drugs are important factors contributing to achieve the desired effect.

**Key words:** Aldactone, hirsutism, metformin

Gonads: Premature sexual development: Clinical and endocrine profile. Do all need intervention?
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**Background and Objective:** Precocious puberty is a common problem encountered in the discipline of endocrinology, which has both medical and social impact. Early diagnosis, management, and counselling are the key to approach this problem. Here, a retrospective review is done to ascertain the mean age of onset, clinical, diagnostic and treatment profile of premature sexual development (PSD).

**Materials and Methods:** A total of 12 patients of premature sexual development (PSD) worked out from August 2011 to April 2013 were analysed.

**Results:** Among all cases of PSD, precocious puberty (PP) was most common followed by exaggerated thelarche (ET) and premature thelarche (PT). Females outnumbered males and all had idiopathic central precocious puberty (CPP) except one who had hypothyroid induced PP. Out of the four males, three had tuber cinereum hamartoma as a cause of CPP. Males presented at a younger age as compared to females. Breast enlargement in females and testicular enlargement in males were the most common presenting features. Mean uterine length (UL) and uterine volume (UV) were in pubertal range. Both basal and post leuprolide LH were in pubertal range and higher in girls in comparison to boys. Long acting GnRH analogue (inj Leuprolide) was started to all cases of CPP and are now under follow-up. Hypothyroid patients with PP responded well to levothyroxin replacement. ET and PT are under follow-up. All female PP group responded well to therapy with no further menstrual cycle.

**Interpretation and Conclusion:** CPP was the most common form of PSD with female predominance, male presented at an early age as compared to female. CPP in females are mostly idiopathic and 75% of males have organic CNS lesion (Tuber cinereum hamartoma). Both basal and 60 min post Leuprolide LH is higher in female. Hypothyroidism is not an uncommon cause of PP. Variants of PP as ET and PT need close follow-up as there are no consensus recommendations for any therapy.

**Key words:** Central precocious puberty, exaggerated thelarche, hypothyroid, ovarian cyst, premature thelarche, tuber cinereum hamartoma

Assessment of menarche in apparently healthy Indian school girls
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**Background:** Given the downward trend in age at menarche and its implications for the reproductive health and well-being of women, little is known about menarcheal age in India in recent past.

**Objective:** To assess the age of menarche in a large representative sample of Delhi school girls.

**Patients and Methods:** This cross-sectional study was carried out in seven schools of different zones of Delhi representing upper middle class of population in the age group of 6-17 years after taking due permissions from school authorities and parents, while verbal assent was taken from each subject. Date of menarche was noted from each girl on memory recall and confirmed from parents by telephonic call or letter. A total of 943 girls were recruited in the study after due sample size calculation. Median age at onset of menarche was estimated using probit analysis.

**Results:** A total of 2,046 female were included in study out of which four were excluded due to non-confirmation of date of birth. Total of 2,042 were analyzed in final analysis and 943 were menstruating at the time of examination. Median age at onset of menarche was 12.4 years (with 95% confidence interval (CI) of 10.2-14.7 year).

**Conclusion:** Results of our study suggest that menarche occurs in Indian girls at the median age of 12.4 years with 95% CI of 10.2-14.7%.

**Key words:** Indian girls, menarche, puberty

Nitric oxide mediated alteration of oocyte maturation in mouse, Mus musculus
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**Objective:** To study the interrelationship of nitric oxide (NO) and ovarian activity in mouse, *Mus musculus*.

**Materials and Methods:** Three groups of mice were administered with saline (control), SNP (NO donor; 0.25 mg/100 g body weight) and L-NAME (NOS inhibitor; 1 mg/100 g body weight) respectively over a period of 9 days. Thereafter mice were sacrificed, plasma was analysed for estrogen and 17-OH progesterone and ovaries were dissected out for the oocyte count and cumulus oocytes complexes (COCs) culture for evaluation of meiotic maturation.

**Results:** Results indicate that 9 days of SNP treatment increased the progesterone level but no significant change was observed in estrogen level. Further in control group, COCs showed a significant increase in the rate of germinal vesicle break down (GVBD) as compare to GV stage. However, both SNP and L-NAME inhibited spontaneous maturation but almost equal number of oocyte showed GV and GVBD in NO donor group while more number of oocyte showed GV stage in NOS inhibitor group.

**Conclusion:** Findings indicate that an optimum level of NO is required for oocyte maturation and any alteration in its level may arrest meiotic maturation through different pathways. Studies are in process to understand the underlying mechanism of such effects.

**Key words:** COCs, estrogen, L-NAME, progesterone, SNP

A comprehensive study on factors associated with delayed menarche in a contemporary Bengali cohort with special reference to ratio of the lengths of second and fourth digits (2D:4D ratio)
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**Introduction:** The age of menarche, a pivotal milestone in the natural history of female sexual development, is influenced by a large number of socio-economic, cultural and biological factors. In our study, we have investigated the influence of a variety of factors, including some novel ones, on the delayed age of menarche.

**Objectives:** (1). To study anthropometric characteristics (height, mid-parental height, weight, BMI), socio-economic status, and Sexual Maturity Rating (SMR) stages in a group with delayed menarche. (2) To study 2D: 4D ratio (ratio of the lengths of second and fourth digits of both hands) in the group with delayed menarche. (3) To investigate the relationship of these factors with delayed age of menarche and compare them with an age and BMI-matched group having normally timed menarche.

**Materials and Methods:** A group of 2,600 girls attending local suburban schools, with low to normal BMI and aged 11-16 completed years, were screened on the basis of predetermined criteria. After screening, a total of 190 girls with delayed menarche (cases) and 424 with normally timed menarche (controls) were selected for this study conducted over a one year period. All the study parameters were evaluated extensively in both groups and data analysis was done by appropriate statistical methods.

**Results and Analysis:** Out of 190 children having delayed menarche and 424 children with normal age of menarche, the 2D:4D ratio (*P* value: 0.002), SMR stages (*P* value: 0.00), and low socio-economic status (*P* value: 0.00) had a significant correlation with delayed age of menarche, while the height percentile (*P* value: 0.642), BMI (*P* value: 0.091), weight (*P* value: 0.12) and mid-parental height (*P* value: 0.26) had no significant correlation.

**Conclusion:** This study is the first to examine such a wide variety of factors influencing delayed menarche in a single cohort of Bengali females at a time and also introduces the index of 2D:4D ratio as a potential biomarker for delayed age of menarche.
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**Introduction:** Idiopathic hypogonadotropic hypogonadism (IHH) is a rare disease with prevalence of 1:10,000 in general population. Various genes associated with IHH have been described and is associated with various disorders. We describe association of IHH with mosaic trisomy 13. Case : A 20-year-old male born of nonconsanguineous marriage presented with lack of development of secondary sexual characters. On examination, he was found to have normal height and eunuchoidal body habitus, micropenis, small testes (bilateral \< 2 ml), gynecomastia, and absence of axillary and pubic hairs. There was also hyposmia, synkinesis, bilateral horizontal nystagmus, and high arched palate. Investigations showed low gonadotropin (luteinizing hormone (LH) = 0.25, follicle stimulating hormone (FSH) = 1.25), low total testosterone (\<10 ng/dl), LH after stimulation with 100 μg tryptorelin subcutaneous (sc) was 11.42 U/l at 40 min. Magnetic resonance imaging (MRI) of hypothalamopituitary region showed normal olfactory bulb and tract, but shallow olfactory sulcus. Karyotype showed homologous Robertsonian translocation of chromosome 13. Audiometry showed no sensorineural impairement, ultrasonography (USG) of abdomen and echocardiogram does not reveal any organ anomaly. The patient was put on expectant follow-up for puberty onset.

**Discussion:** This case fits classical IHH except for tryptorelin stimulated LH rise. Bauman variant of IHH has been described to have similar increase in LH. The patient is being followed-up for reversibility. Karyotype showed presence of Robertsonian translocation of chromosome 13. Features of Patau syndrome which is associated with trisomy 13 are absent in our case. Mosaic trisomy 13, which can otherwise be rare incidental finding, has not been described in association with IHH.

**Conclusion:** An association of two very rare diseases mosaic trisomy 13 with IHH cannot be ruled out.

**Key words:** Hypogonadism, hypogonadotrophic, idiopathic, trisomy 13

Effect of metformin therapy on serum markers in adolescent and young women with polycystic ovary syndrome
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Polycystic ovary syndrome (PCOS) is the most common endocrinopathy in women. The role of metformin in this condition has been a subject of debate. At present metformin is reserved for patients with evidence of impaired glucose. In this context we ventured to study the impact of metformin in normoglycemic women with PCOS.

**Objectives:** To evaluate the impact of metformin therapy on markers of insulin resistance and hyperandrogenism in women with newly diagnosed PCOS.

**Materials and Methods:** Sixty women with newly diagnosed PCOS between the age of 18 and 45 years were enrolled after informed consent. Patients with type 2 diabetes, impaired fasting glucose (IFG), impaired glucose tolerance (IGT), thyroid dysfunction, pregnancy or contemplating pregnancy, or taking oral contraceptive pills (OCPs) or metformin were excluded. After baseline measurements including anthropometry and laboratory parameters, patients were started on metformin sustained release 1 g initially titrated to 1.5 g after 2 months. Measurements were repeated at the end of the study. Height, weight, body mass index (BMI), waist measurements, adiponectin, fasting insulin, sex hormone binding globulin (SHBG), testosterone (hormones by enzyme-linked immunosorbent assay (ELISA)), and fasting glucose by glucose oxidase-peroxidase (GOD-POD) were measured. Waist-hip ratio, free androgen index (FAI), and homeostasis model assessment-estimated insulin resistance (HOMA-IR) were calculated.

**Results:** After 6 months of metformin therapy there was a significant reduction in insulin (*P* \< 0.05, 95% CI: 1.11-1.61), HOMA IR (*P* \< 0.05, 95% CI: 1.12-1.36), total testosterone (*P* \< 0.05, 95% CI: 0.17-0.24), and free androgen index (*P* \< 0.05, 95% CI: 0.93-1.14). Paradoxically adiponectin was also significantly lower (*P* \< 0.05, 95% CI: 1.43-1.94) after metformin therapy.

**Conclusion:** Six months of metformin therapy favorably altered markers of insulin resistance and hyperandrogenism in normoglycemic women with PCOS. However, there was also a paradoxical lowering of adiponectin.

**Key words:** Adiponectin, FAI, HOMA-IR, metformin, PCOS, SHBG, total testosterone

Beta cell function and insulin resistance in lean patients with polycystic ovary syndrome
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**Introduction:** Obesity is a major factor in development of insulin resistance and metabolic features in polycystic ovary syndrome (PCOS) patients. Nearly two-thirds of Indian patients with PCOS are lean (30 of 37 confirmed cases of PCOS in our previous community prevalence study were lean), in contrast to the Caucasians. Metabolic parameters insulin resistance and beta cell function have not been characterized well in this group of lean PCOS.

**Objective:** To study the metabolic features, beta cell function, and insulin resistance in lean PCOS patients attending the endocrine clinic.

**Materials and Methods:** Twenty lean, (body mass index (BMI) \<23 kg/m^2)^ cases of PCOS (diagnosed by Rotterdam criteria) were compared with 44 obese PCOS cases, age 42 years, and BMI comparable controls and 31 obese controls. All subjects underwent detailed history, examination, and 2 h oral glucose tolerance test (OGTT). Various indices were calculated from the glucose and insulin values measured in OGTT, beta cell function was also assessed by measuring fasting C-peptide.

**Result:** Waist-hip ratio, post glucose blood glucose (PPG), and fasting glucose to insulin ration (FGIR) were different in lean cases and controls but other parameters; HOMA-IR, c-peptide, and prevalence of metabolic syndrome (International Diabetes Federation (IDF) criteria) were similar. Compared with obese PCOS, lean PCOS cases had less prevalence of hirsutism, acanthosis, and metabolic syndrome; low fasting glucose, PPG, and FGIR; but higher luteinizing hormone (LH). Serum alanine aminotransferase (ALT) was significantly higher in obese PCOS cases than obese controls. Fasting C-peptide and homeostasis model assessment (HOMA)-B were comparable in all groups of patients and controls.

**Conclusion:** Metabolic characteristics and beta cell function in lean PCOS patients is similar to obese PCOS. Drawback of the study is the small sample size of lean patients and a hospital based study, which could mean patients who were more symptomatic were enrolled.

**Key words:** Beta cell function, insulin resistance, lean, PCOS

Hayek Peake syndrome: A rare cause of hypothalamic dysfunction without structural lesion
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**Introduction:** Hayek Peake syndrome is a rare syndrome of hypothalamic dysfunction manifested with hypodipsic hypernatremia, hyperprolactinemia, dyslipidemia and short stature.

**Case Report:** A 15-year-old male was referred in view of short stature, delayed puberty and chronic hypernatremia. Born of non-consanguineous marriage with uneventful birth history; normal mile stones was apparently normal until 10 years of age. Since then there was poor growth in height, with no development of secondary sexual characters. There was a history of recurrent episodes of lower limb weakness, unexplained fever with severe hypernatremia (160-185 mmol/L) and hypokalemia. There was no h/s/o of polyuria, polydipsia, hypothyroidism, hypocortisolism, raised inner cerebral trauma and head trauma. On examination, height and weight were less than 3^rd^ percentile, prepubertal genitalia, dysmorphic features, dehydration with blood pressure-90/60 mmHg and normal systemic examination. On evaluation, found to be euthyroid, eucortisolic, hypogonadotropic hypogonadism, hypernatremia, hypokalemia, hypertriglyceridemia, hyperprolactinemia, with no obvious structural lesion on contrast enhanced magnetic resonance imaging.

**Discussion:** The present case has short stature, hypogonadotropic hypogonadism, hyperprolactinemia, hypodipsic hypernatremia and behavioral abnormality. All these are indicative of extensive hypothalamic derangement, despite structural abnormality being absent in this patient. Associated dyslipidemia was found during the hypernatremic episodes. Corpus callosal defects, detected in some of the previous similar cases, are found absent in this case.

**Conclusions:** There are very few cases reported so far if any case presents with chronic/persistent hypernatremia along with hypodipsia, other hypothalamic abnormalities are to be carefully looked for.

**Key words:** Dyslipidemia, Hayek Peake syndrome, hyperprolactinemia, hypodipsic hyponatremia, hypogonadotropic hypogonadism

Prolactin unresponsiveness and paradoxical elevation of estrogen despite gonadotropin suppression in postmenopausal women suffering from severe acute illness
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**Introduction:** Postmenopausal women constitute an ideal model for studying the extent of hypothalamo-pituitary-gonadal (HPG) axis suppression in critical illness as the gonadotropins are normally high and non-cyclical in them.

**Objectives:** The objective of this study is (i) to assess the impact of acute severe illness on the HPG axis in postmenopausal women, (ii) to correlate the severity of illness with (a) activity of the HPG axis, (b) the activity of the hypothalamo-pituitary-adrenal axis, (c) activity of the hypothalamo-pituitary-thyroid axis and (d) serum prolactin.

**Methods:** A total of 35 postmenopausal women older than 60 years admitted to medical intensive care with a simplified acute physiology score II (SAPS II) more than 30, consistent with a predicted in-hospital mortality of greater than 10% were recruited. On day 5 of their hospital stay, blood samples were collected for estradiol, luteinizing hormone (LH), follicle stimulating hormone (FSH), cortisol, androstenedione and prolactin and thyroid profile. As controls, 35 apparently healthy postmenopausal women were recruited.

**Results:** Levels of LH, FSH, free thyroxin (fT~4~) and triiodothyronine were lower while estradiol, cortisol and androstenedione were higher among patients in comparison with healthy controls. Prolactin levels were similar in patients and controls. Among sick patients both FSH and fT~4~ showed a negative correlation (*P* \< 0.05) with the SAPS II score.

**Conclusions:** Estrogens are paradoxically elevated despite gonadotropin suppression in critically ill postmenopausal women, suggesting a non-ovarian origin of the same. Prolactin remained unaltered despite illness in patients, possibly reflecting atrophy of lactotrophs in menopause.

**Key words:** Critical illness, estradiol, gonadotropins, postmenopausal, prolactin

Case report of P450 oxidoreductase deficiency presenting as primary amenorrhea
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**Objective:** A case report of P450 oxidoreductase deficiency (PORD) presenting as primary amenorrhea.

**History:** A 19-year-old female patient presented with primary amenorrhea and poor development of breasts. On examination, she had eunuchoid proportions with poor breast contour and had clitoromegaly with Prader stage 3 since birth. No progression in the size of the clitoris noticed.

**Investigations:** Karyotype was 46XX with hormonal profile suggestive of low estradiol and high testosterone with a normal cortisol and 17 hydroxyprogesterone. Hence, aromatase deficiency was suspected. However, genetic testing for aromatase deficiency was negative. Urinary steroid profiling by gas chromatography/mass spectrometry was suggestive of PORD, which was confirmed by genetic analysis.

**Conclusion:** PORD should be considered as one of the differential diagnosis in a case of eunuchoid 46XX hypogonadism with primary amenorrhea and ambiguity.

**Key words:** Amenorrhea, P450 oxidoreductase deficiency

A case of pregnancy with pituitary macroadenoma and apoplexy
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**Introduction:** Pregnancy is associated with an increase in size of pituitary gland and preexisting adenomas. Occurrence of new tumors is rare during pregnancy. But macroadenomas can present for the first time during pregnancy and rarely undergo apoplexy with hypopituitarism.

**Case Report:** A 20-year-old antepartum female with 3 months of gestation (G2P1L1) presented with complaints of headache since 1 week, drooping of right upper eyelid, and diplopia since 5 days. Clinical examination revealed decreased visual acuity with normal fundus and right third cranial nerve palsy. Magnetic resonance imaging (MRI) brain showed pituitary macroadenoma with apoplexy. Hormonal evaluation was done. Basal cortisol level was suggestive of adrenal insufficiency. Thyroid profile was suggestive of inappropriately normal thyroid stimulating hormone (TSH) with low levels of triiodothyronine (T3) and thyroxine (T4) for the gestational age. Serum prolactin levels were within normal limits. Patient was started on steroid and thyroxine supplements with stress dose advice for delivery. Patient delivered a healthy male baby by lower segment cesarean section (LSCS). Patient had significant polyuria and polydipsia during follow-up after delivery. Water deprivation test was suggestive of central diabetes insipidus. Patient was started on desmopressin. Repeat MRI pituitary showed empty sella.

**Conclusion:** This case report illustrates that pituitary macroadenomas may rarely present for the first time during pregnancy as apoplexy. The increased size and vascularity of the gland during pregnancy may predispose to apoplexy.

**Key words:** Apoplexy, pregnancy, pituitary macroadenoma

A case of breast tumor in a male with complete androgen insensitivity
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**Introduction:** Androgen insensitivity (testicular feminization) syndrome is a rare inherited form of male pseudohermaphroditism that occurs in phenotypically normal woman with adequate breast development, normal external genitalia, a vagina of variable depth, absent uterus, and sparse or absent pubic hair and axillary hair. These patients have male karyotype (XY) and negative sex chromatin. The gonad (undescended testes) may be intra-abdominal, inguinal, or labial. The probable explanation of the syndrome is the absence of the cytosolic androgen binding protein receptor that is normally present in the androgen responsive tissue.

**Case Report:** A 17-year-old female presented with chief complaints of not attaining menarche and swelling in left breast. She was operated outside for this swelling. Physical examination revealed normal breast development, normal external gelia, sparse pubic hair, absent axillary hair, and bilateral inguinal masses. Ultrasonography (USG nita) of the abdomen showed absent uterus and ovaries in the pelvis. Subsequent cytogenetic analysis confirmed 46 XY karyotype. Review of the histopathological examination of the excised breast tissue was suggestive of multiple papilloma with hyperplasia of unusual type and immunohistochemistry markers positive for ck-5, p63, and actin.

**Conclusion:** Cancer of breast is rare in males, but the risk is increased in those with androgen hypoinsensitivity caused by longer glutamine repeats in the androgen receptor (AR) seen with partial androgen insensitivity syndromes (PAIS) or mild androgen insensitivity syndromes (MAIS). Breast cancer has not been reported in complete androgen insensitivity syndromes (CAIS). The above case report illustrates a rare presentation of breast papilloma with hyperplasia of unusual type in a male with complete androgen insensitivity syndrome.
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Metabolism: Efficacy of laparoscopic sleeve gastrectomy and weight neutral intensive medical management in obese patients with type 2 diabetes mellitus
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**Background:** There are dearth of studies comparing laparoscopic sleeve gastrectomy (LSG) and weight neutral intensive medical treatment (IMT) in obese type 2 diabetes mellitus (T2DM) patients. This study compares these modalities in terms of weight, metabolic, and quality of life (QOL) parameters.

**Materials and Methods:** We evaluated the efficacy of LSG (*n* = 14) vs. IMT (*n* = 17) comprising of exenatide, metformin, low calorie diet, and if required, insulin detemir in 31 obese T2DM patients with target glycosylated hemoglobin (HbA1c) \<7%. The mean (±SD) age of the patients was 49.6 ± 11.9 years and 74% were women. The mean duration of diabetes was 8.5 ± 6.1 years and mean HbA1c was 8.6 ± 1.3%. Primary end point was excess body weight (EBWL) loss at final follow-up.

**Results:** The mean duration of follow-up was 12.5 ± 5.0 months. EBWL was 61.2 ± 17.6% in LSG group and 27.4 ± 23.6% in IMT group (*P* \< 0.001) at final follow-up. Glycemic outcomes improved in both groups with mean HbA1c of 6.6 ± 1.5% in LSG group and 7.1 ± 1.2% in IMT group. In LSG group, there was resolution of diabetes and hypertension in 36% and 29% of patients, respectively, while none in the IMT group. Homeostasis Model of Assessment-Insulin Resistance (HOMA-IR), high-sensitivity C-reactive protein (hsCRP), ghrelin, and leptin decreased while adiponectin increased significantly in LSG group compared to IMT group. QOL improved in multiple parameters in LSG compared to IMT.

**Conclusions:** In obese T2DM patients, LSG is superior in terms of weight, resolution of comorbidities, and QOL compared to IMT.

**Key words:** Exenatide, laparoscopic sleeve gastrectomy, type 2 diabetes mellitus, weight neutral medical management

Is urban residence associated with better diabetes outcomes? -- A cross sectional study
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**Background:** Several studies have shown that knowledge and awareness about diabetes helps in better management. It is not known whether area of residence has such an impact.

**Objectives:** To know if area of residence and frequent evaluation have an effect on diabetes knowledge and consequently its management.

**Materials and Methods:** Two hundred and twenty-six consecutive patients with Type 2 diabetes were evaluated for their knowledge and self-care practices using a semi-structured questionnaire. Complications like retinopathy, nephropathy, neuropathy, ABI, stroke occurrence and ECG abnormalities were evaluated. Statistical methods used included frequencies and χ^2^ test.

**Results:** Of the 226 respondents, 76.1% were from town, 20.8% from city and 3.1% from village, with a mean age of 52.7 ± 0.68 years. Diabetes duration 101.9 ± 5.496 months (8.49 ± 0.5 years). Mean Fpg, ppg, HbA1C, HDL-C, LDL-C, and triglycerides were 168.19 ± 4.75 mg/dL, 251 ± 6.7 mg/dL, 8.8 ± 0.14%, 42.81 ± 3.37 mg/dL, 106 ± 2.26 mg/dL, and 164.16 ± 7.5 mg/dL, respectively. The HbA1c and Fpg values did not differ significantly with their area of residence, whereas mean ppg was better in village (240.20) followed by town (251.94) and city (262.45). Diabetic retinopathy and neuropathy were significantly more common with non-city residence (*P* = 0.000). It was found that majority of the city (48.9%) and town (73.8%) dwellers checked sugars once a month while few respondents (14.3%) hailing from village checked sugars once in a month (*P* = 0.007). Significantly larger number of people in city knew HbA1c and its targets (*P*-score = 0.000). Comprehensive testing was done by more people in city than others (*P* = 0.03).

**Conclusion:** Area of residence has an impact on knowledge and was also associated with frequent evaluation. But this was not associated with better control or fewer complications in our patient population. Further studies are necessary to address this gap.
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A 24-week open-label, comparative observational study to evaluate the efficacy and safety of vildagliptin and other anti-diabetic drugs in Indian patients with type 2 diabetes
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**Objective:** The objective of this study was to investigate the safety and efficacy of Vildagliptin as monotherapy or as add-on to metformin and compare with other anti-diabetic drugs (OADs) therapy (comparator).

**Patients and Methods:** This was an open-label, comparative, observational study, in Indian type 2 diabetes mellitus population with glycosylated hemoglobin (HbA1c) \>7.5-11%, conducted at 36 centers across different cities of India. Patients were stratified by the treating physicians into two treatment groups: Group 1 (Vildagliptin or Vildagliptin plus metformin) and Group 2 (OADs either as monotherapy or as the combination with metformin). Group 2 included OADs other than Vildagliptin such as sulfonylureas, thiazolidinediones, metiglinides, α-glucosidase inhibitors and insulin.

**Results:** In this study, 796 patients (445 in Vildagliptin and 351 in OADs group) were enrolled and observed for 24 weeks. During this period, significantly higher hypoglycemic events were reported from OADs group, compared to Vildagliptin group (5.1% vs. 1.8%, *P* = 0.014; 95% Cl: 0·15-0·80) The use of Vildagliptin demonstrated notably decreased risk of adverse events (AEs) (0·50 (95% CI, 0·29-0·87), with more number of patients in OADs group, than in Vildagliptin group reporting for AEs (8.5% vs. 4.3%; *P* = 0.017; 95% Cl: 0.29-0.87). The study results show that Vildagliptin was well tolerated by study cohort. There were no deaths, SAEs or discontinuation reported in either group during the course of study. Significantly more number of patients in Vildagliptin than in OADs group, achieved HbA1c change of ≥0.7%, (81.3% vs. 68.7%, *P* \< 0.001) and higher mean reduction in HbA1c levels, (−1.4% vs. −1.11%; *P* \< 0.001). A similar higher reduction in mean postprandial glucose and fasting plasma glucose levels was demonstrated in Vildagliptin groups.

**Conclusions:** Vildagliptin was associated with significantly lower hypoglycemic events and better glycemic control compared with other OADs. Vildagliptin appears to be an effective treatment option for Indian diabetes patients.

**Key words:** Diabetes, other anti-diabetic drugs, Vildagliptin

Metabolic profile of patients post-liver transplantation: A tertiary center experience
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**Introduction:** The prevalence of medical complications such as hypertension, hyperlipidemia, weight gain and diabetes has been rising along with increased life expectancy after liver transplantation. These metabolic complications lead to cardiovascular complications and increased late morbidity and mortality. Post-transplant risk stratification and aggressive treatment of metabolic complications, including modification of risk factors is imperative to prevent serious complications.

**Methods:** We retrospectively studied 180 consecutive liver transplant recipients at Amrita Institute of Medical Science, Kochi, Kerala. We gathered demographic and biochemical data, pre-transplant Model for End-Stage Liver Disease scores, etiology of liver disease, daily glucose kinetics, type of insulin, requirement for diabetes medications at 12 months, immunosuppression therapy (including steroids), was assessed.

**Results:** Of the 180 patients identified, 121 had complete data and were included in the analysis. Male:Female ratio was 4:1.15% had pre-existing diabetes. Nearly, 14% developed post-transplant diabetes. Nearly, 30% of the post-transplant patients became normoglycemic at 6 months post-transplant. Diabetes, family history of diabetes and excess body weight at baseline were the risk factors for incidence of metabolic syndrome. Detailed analysis of the results will be discussed during the conference.

**Conclusion:** New onset diabetes after transplantation and metabolic syndrome are associated with increased risks of graft rejection, infection, cardiovascular disease and death. Whilst the pathophysiology remains unclear, being vigilant for this important complication and starting hyperglycemic management in a timely fashion may reduce the incidence of and morbidity associated with these metabolic complications.

**Key words:** Liver transplantation, nodat, post-transplant metabolic syndrome

Ferritin as a marker of insulin resistance in polycystic ovarian syndrome
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**Objective:** Insulin resistance is associated with increased serum ferritin levels in patients with type 2 diabetes mellitus. Patients with polycystic ovarian syndrome (PCOS) are also insulin resistant so we hypothesized that these patients will also have increased ferritin levels, which may correlate with insulin resistance in these patients. Thus, this study was carried out to assess the serum ferritin levels in PCOS patients and to find out its association it with insulin resistance.

**Research Design and Methods:** This was a cross-sectional case-control study, which included 50 cases with PCOS diagnosed according to the Rotterdam criteria who were compared with age and body mass index (BMI) matched 40 controls. The cases underwent biochemical evaluation for serum ferritin (enzyme-linked immunosorbent assay), fasting blood glucose, fasting insulin levels and testosterone and controls underwent evaluation for serum ferritin.

**Results:** Mean age of patients was 24.24 ± 5.24 years and controls were 29.62 ± 5.32 years. Mean ferritin level in PCOS cases was 25.64 ± 16.51 and in controls was 8.41 ± 10.51 (*P* \< 0.001). In bivariate analysis, BMI was found to be correlated with ferritin levels; r = 0.634, *P* = 0.049 in BMI of less than 23 kg/m^2^ and BMI more than 23 kg/m^2^ r = 0.526, *P* \< 0.001. In a binary logistic regression analysis model for finding best predictor of insulin resistance, which included ferritin, BMI and age and testosterone, BMI came as the best predictor of insulin resistance (*P* = 0.037, r^2^= 0.154).

**Conclusions:** Ferritin levels were higher in PCOS cases compared with the controls. As BMI increases ferritin levels increase, ferritin levels correlated well with BMI. BMI is a good predictor of insulin resistance in PCOS patients.

**Key words:** Ferritin, insulin resistance, polycystic ovarian syndrome

Pioglitazone reduces 1,25(OH)

2

vitamin D/25(OH) vitamin D ratio: Is pioglitazone 1-alpha hydroxylase inhibitor?

Anubhav Thukral, S. Chitra, Rana Bhattacharya, Sujoy Ghosh, Satinath Mukhopadhyay, Subhankar Chowdhury

**Background:** Pioglitazone increases the risk of fracture by altering bone health. It has been hypothesized that these effects are due to direct action of pioglitazone on bone, which leads to differentiation of mesenchymal stem cells toward an adipocyte lineage rather than osteoblast lineage. Other studies suggest that pioglitazone causes increased urinary calcium loss and thus alters calcium homeostasis. We hypothesize that this might be due to alteration of vitamin D metabolism by pioglitazone.

**Methods:** In our open-labeled interventional study, we evaluated the effect of pioglitazone (45 mg/day) on serum calcium, phosphate, alkaline phosphatase, intact parathormone (PTH), 25(hydroxy (OH)) vitamin D, 1,25(di-hydroxy (OH)~2~) vitamin D, urinary calcium and urinary phosphate excretion in patients with type 2 diabetes, who were on metformin monotherapy.

**Results:** A total of 13 subjects were included in our study. After 12 weeks of pioglitazone therapy, there was a significant reduction in the ratio of 1,25(OH)~2~ D/25(OH)D suggesting suppression of 1-alpha hydroxylase activity. No effect on calcium excretion was observed; although, serum calcium did show a downward trend, but failed to achieve levels of statistical significance.

**Conclusion:** Pioglitazone reduces 1,25(OH)~2~ vitamin D levels, due to inhibition of 1-alpha hydroxylase activity and may affect bone mineral metabolism.

**Key words:** Pioglitazone, vitamin D

Efficacy and tolerability of saxagliptin in patients with type 2 diabetes mellitus and a history of cardiovascular disease
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Subgroup analysis of data from patients with type 2 diabetes mellitus (T2DM) and a history of cardiovascular disease (CVD) (previous event or CVD diagnosis) included data from three phase three studies: Saxagliptin (SAXA) + metformin (MET) versus MET as initial therapy (NCT00327015), (SAXA) + MET versus glipizide (GLIP) + MET (NCT00575588) and SAXA versus placebo (PBO) add-on to insulin ± MET (NCT00757588). Glycemic efficacy and adverse events (AEs) for SAXA versus PBO or comparator were analyzed in patients with/without a history of CVD. No treatment-by-subgroup interactions (*P* \< 0.1) were noted for change from baseline in A1C \[[Table 1](#T1){ref-type="table"}\]. AEs were comparable across CVD groups and reported by 47-69% of patients. Symptomatic confirmed hypoglycemia (fingerstick glucose ≤50 mg/dL) was reported in 0-9% of patients, with more episodes reported for patients receiving GLIP \[[Table 2](#T2){ref-type="table"}\]. SAXA improves glycemic control and is generally well-tolerated in patients with T2DM regardless of CVD history.
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Add-on treatment with exenatide once weekly versus daily basal insulin in patients with A1C ≥8.5%
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In general, basal insulin (b-INS) is the add-on treatment of choice for patients with severe hyperglycemia, but it can be questioned whether b-INS is the best option. The current *post-hoc* analyses compared the efficacy and tolerability of exenatide once weekly (EQW) with those of b-INS in patients with type 2 diabetes mellitus on metformin±sulphonylurea with baseline A1C ≥8.5%. Data were pooled from two 26-week, randomized, controlled studies (EQW vs. insulin glargine and EQW vs. insulin detemir; *N* = 137 \[EQW\], 126 \[b-INS\]). Patients treated with EQW had a significantly greater decrease in A1C from baseline than those treated with b-INS (least squares \[LS\] mean ± SE change: −2.0% ± 0.08 vs. −1.6% ± 0.08; *P* = 0.0008) and were significantly more likely to reach an A1C goal of \<7.0% (39.4% vs. 23.0%; *P* = 0.002). Decreases in FPG were smaller in the EQW group (−52.2 ± 3.70 vs. −61.9 ± 3.74 mg/dL; *P* = 0.062\]). Mean ± SE weight loss with EQW was −2.4 ± 0.23 kg, whereas weight gain with b-INS was 2.0 ± 0.24 kg (LS mean difference between groups, −4.4 kg; *P* \< 0.0001). Patients in the EQW group were significantly more likely to achieve a composite goal (A1C \<7.0%, no weight gain and no hypoglycemia \[requiring assistance or self-treated with blood glucose \<54 mg/dL\]) than were patients in the b-INS group (33.6% vs. 3.2%; *P* \< 0.0001). Hypoglycemia occurred at a rate of 0.08 exposure-adjusted events per patient year in the EQW group and 0.37 events in the b-INS group. The most common adverse events were nausea (28.5%), nasopharyngitis (16.8%) and hypoglycemia (14.6%) in the EQW group and hypoglycemia (38.9%) and nasopharyngitis (19.0%) in the b-INS group. Results of these analyses show that treatment with EQW was associated with significantly greater reductions in A1C and body weight and a lower rate of hypoglycemia than treatment with b-INS. Results from this *post-hoc* analysis suggest that EQW is a treatment alternative to b-INS in patients with A1C ≥8.5% who are receiving treatment with oral antihyperglycemic medications and are concerned about weight gain and the risk of hypoglycemia.

**Key words:** Exenatide, hypoglycemia, insulin

Dapagliflozin as monotherapy in drug-naïve Asian patients with type 2 diabetes mellitus inadequately controlled on diet and exercise
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Dapagliflozin (DAPA), a selective SGLT2 inhibitor, improves glycemic control in diverse patient populations as monotherapy or in combination with other glucose-lowering drugs. We assess DAPA as monotherapy in drug-naïve Asian patients inadequately controlled on diet and exercise (hemoglobin A1c \[HbA1c\] 7.0-10.5%) in a 24-week double-blind study (NCT01095653) that randomized patients to placebo (PBO; *N* = 132) or DAPA (5 or 10 mg; *N* = 128 and 133, respectively) groups. Baseline characteristics were balanced across groups. Most patients (89%) were Chinese. Median duration of type 2 diabetes mellitus was 0.2 years. At week 24 (last observation carried forward \[LOCF\]), DAPA 5 and 10 mg provided dose-dependent, statistically significant reductions in HbA1c versus PBO (primary endpoint) and in fasting plasma glucose (FPG), postprandial glucose (PPG), body weight and proportion of patients with HbA1c \<7% (secondary endpoints) \[[Table 1](#T3){ref-type="table"}\]. Adverse events (AEs) were balanced across groups. Few patients had serious AEs or AEs leading to discontinuation. Hypoglycemia was uncommon (1.5, 0.8 and 0.8% in the PBO, DAPA 5 mg and 10 mg groups, respectively); none led to discontinuation. Genital infections were more common with DAPA; 0.8%, 3.1% and 4.5% of PBO, DAPA 5 mg or 10 mg patients, respectively. Urinary tract infections occurred in 3.0%, 3.9% and 5.3% of patients, respectively. No AEs of renal failure or pyelonephritis and no deaths occurred. In summary, DAPA as monotherapy in drug-naïve Asian patients was well-tolerated, significantly improving glycemic control with the additional benefit of modest weight loss.

###### 

Dapagliflozin efficacy and safety at 24 weeks in Asian patients
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Metabolic profile of patients post-liver transplantation: A tertiary center experience
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**Introduction:** The prevalence of medical complications such as hypertension, hyperlipidemia, weight gain and diabetes has been rising along with increased life expectancy after liver transplantation. These metabolic complications lead to cardiovascular complications and increased late morbidity and mortality. Post-transplant risk stratification and aggressive treatment of metabolic complications, including modification of risk factors is imperative to prevent serious complications.

**Methods:** We retrospectively studied 180 consecutive liver transplant recipients at Amrita Institute of Medical Science, Kochi, Kerala. We gathered demographic and biochemical data, pre-transplant Model for End-Stage Liver Disease scores, etiology of liver disease, daily glucose kinetics, type of insulin, requirement for diabetes medications at 12 months, immunosuppression therapy (including steroids), was assessed.

**Results:** Of the 180 patients identified, 121 had complete data and were included in the analysis. Male:Female ratio was 4:1.15% had pre-existing diabetes. Nearly, 14% developed post-transplant diabetes. Nearly, 30% of the post-transplant patients became normoglycemic at 6 months post-transplant. Diabetes, family history of diabetes and excess body weight at baseline were the risk factors for incidence of metabolic syndrome. Detailed analysis of the results will be discussed during the conference.

**Conclusion:** New onset diabetes after transplantation and metabolic syndrome are associated with increased risks of graft rejection, infection, cardiovascular disease and death. Whilst the pathophysiology remains unclear, being vigilant for this important complication and starting hyperglycemic management in a timely fashion may reduce the incidence of and morbidity associated with these metabolic complications.
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General: Acromegaly: Clinical profile and treatment outcome: A single center experience
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**Introduction:** Acromegaly is a rare disease, most commonly caused by GH secreting pituitary adenoma.

**Objective:** To analyze clinical profile and treatment outcome of patients with acromegaly.

**Materials and Methods:** A retrospective analysis of clinical features, radiological features, and treatment outcome of 213 patients with acromegaly (between 1996 and 2012) was carried out.

**Results:** Two hundred and thirteen patients with acromegaly (one hundred and seven males and one hundred and six males) were evaluated during this period, with a mean age at diagnosis 35.4 years. Of these, 95.3% were having macroadenoma, while only 3.5% patients were having microadenoma, and 9.38% of patients were giants. Most common mode of presentation was acral/facial enlargement (94.3%), followed menstrual irregularities (67.1% of females), headache (66.7%), hyperhidrosis (54.9%), visual field defects (42.3%), joint pain (39.4%), galactorrhea (32.2% of females), obstructive sleep apnea (24.6%), hypertension (23.9%), and diabetes mellitus (23.0%). One hundred and seventy five patients underwent surgery, sixty five patients received radiotherapy, and eight patients received medical treatment. Cures \[GH values (basal or after an oral glucose tolerance test) 1 ng/mL and normal IGF-I \] were observed in 24.5% after surgery and 42.1% after radiotherapy over a median follow-up of 48 months.

**Conclusion:** As compared to the literature, acromegaly presented at an early age in our cohort and 9.38% of them were giants. Most of them were having macroadenoma (particularly invasive and aggressive tumors) leading to low cure rates following surgery.
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Macroprolactinoma: Single centre experience
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**Introduction:** Prolactinomas are the commonest pituitary adenomas. Ten percent of prolactinomas are macroprolactinomas.

**Methods:** A retrospective analysis of the clinical features, radiological features, and outcome of patients diagnosed with macroprolactinomas between 2000 and 2012 at our institute was carried out.

**Results:** One hundred patients with macroprolactinoma (fifty females and fifty males) were evaluated during this period. Most common mode of presentation was symptoms of hypogonadism (75%) followed by symptoms of mass effect (70%), i.e., headache, vomiting, visual defect, cranial nerve palsy, and galactorrhoea (26%). The mean prolactin level at presentation was 3585 ng/mL and median prolactin level was 1269 ng/mL (Range: 107-66261 ng/mL). The mean volume of the tumor was 16.4 cm3 and median volume was 9.3 cm3. (Range: 1.1-80 cm3). All the patients were treated with dopamine agonist cabergoline. The median dose of cabergoline was 1 mg/week. Ninety patients received cabergoline as primary treatment and ten after surgery. Thirty patients were resistant to cabergoline. In cabergoline-resistant patients, 16 were treated with high-dose cabergoline treatment only while 14 were treated by trans-sphenoid surgery in addition to high-dose cabergoline. Radiotherapy was given in addition to surgery in eight patients. The median duration of follow-up was 3 years. In resistant tumors, multi-modality treatment resulted in response in 29 patients (total response in 14, partial response in 15). Cabergoline treatment could not be discontinued in any of the patients except in one patient who received radiotherapy.

**Conclusion:** We report 1:1 male-to-female ratio in macroprolactinomas. The commonest presentation was due to hypogonadism followed by symptoms of mass effect. We report higher prevalence of dopamine agonist (DA)-resistant macroprolactinomas and the need for ongoing DA treatment. The multi-modality treatment results in response in most of the resistant cases.
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ACTH-secreting macroadenoma: Experience from a single tertiary care center in India
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**Objective:** To study clinical profile and treatment outcome of patient of Cushing disease with macroadenoma to a single tertiary care center in India.

**Patients and Methods:** Medical records of 42 patients diagnosed with Cushing macroadenoma from 1993 to 2012 were reviewed.

**Results:** Out of 42 patients, 16 were male and 24 were female. Mean age of presentation was 27.6 ± 10.67 years. Median duration between onset of symptoms and diagnosis was 24 months. Median ACTH value was 97.1 pg/mL. Visual field defects and mass effect were found in 15 patients. Mean maximum dimension of tumor was 20.7 ± 9.8 mm. All 42 patients underwent TSS. Six patients underwent early remission and eleven patients showed (first TSS: cure rate: 37%) delayed remission. Among 25 uncured patients and 4 relapses, 8 lost to follow-up and 2 died. Nineteen underwent second line of management -- seven: second TSS, two: medical management and ten: radiotherapy. Cure rate of second TSS was 12.5% and radiotherapy was 71%.

**Conclusion:** Largest series of Cushing macroadenoma. Compared to literature, we have large proportion of macroadenoma, young macros (\<30 years: 60%), and larger tumor size. The peculiar feature is delayed cure 65% of cured patients. Results of second TSS were poor and radiotherapy is very effective mode of therapy.
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